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 Influenza A virus encodes M2, a proton channel that has been shown to be 
important during virus entry and assembly. The primary aim of this thesis was to 
investigate the role of the membrane proximal region, residues 46-69, of the M2 
cytoplasmic tail during virus replication. A cholesterol recognition/interaction amino 
consensus (CRAC) motif, previously identified in the membrane proximal region of 
M2 in some influenza A virus strains, was suggested to play a role in virus 
replication by mediating incorporation of M2 into budding virus particles. Alteration 
or completion of the M2 CRAC motif in two different recombinant virus strains 
caused no changes in virus replication in tissue culture; however, viruses lacking an 
M2 CRAC motif had decreased morbidity and mortality in the mouse model of 
infection. In order to further investigate the role of the membrane proximal residues 
of M2 in basic virus replication, scanning and directed alanine mutants were 
generated and analyzed in trans-complementation assays and recombinant viruses. 
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The membrane proximal residues 46-69 tolerated numerous mutations with little, if 
any, affect on virus replication suggesting that the identity of individual amino acids 
in this region are less important than the overall protein structure for the M2 protein 
function. The requirement during virus replication of the ectodomain and the 
cytoplasmic tail of M2, which includes the membrane proximal region, was further 
characterized using the influenza C virus CM2 protein and a chimeric influenza A 
virus M2 protein (MCM) containing the CM2 transmembrane domain. While M2, 
CM2, and MCM could all alter cytosolic pH to varying degrees when expressed 
from cDNA, only M2 and MCM could at least partially complement an M2-null 
virus in a trans-complementation system. This data suggests that while the CM2 ion 
channel activity is similar to that of M2, sequences in the ectodomain and/or 
cytoplasmic tail play important roles in infectious virus production. This thesis 
suggests that the structure of the membrane proximal region of the M2 cytoplasmic 
tail may stabilize the membrane distal region, which mediates genome incorporation. 
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Influenza Virus Pathogenesis 
 Influenza A virus is a member of the Orthomyxovirdae family whose genome 
consists of 8 negative-sense RNA segments which encode 10 or 11 proteins. Influenza A 
virus remains a major public health burden even with widespread annual vaccination and 
the availability of antivirals. Each year more than 230,000 hospitalizations and 50,000 
deaths in the United States alone are associated with influenza related illness (148, 149). 
Two types of vaccines are currently on the market, a trivalent inactivated vaccine (TIV) 
and a trivalent live attenuated influenza vaccine (LAIV) [reviewed in (29)]. However, 
annual vaccination is indicated for both vaccines because neither generates long term 
immunity to the ever evolving influenza viruses. Influenza viruses undergo two forms of 
genetic variation. The immune response of infected individuals, primarily against the 
viral glycoproteins hemagglutinin (HA) and neuraminidase (NA), provides selective 
pressure that allows naturally occurring variants with replication advantages, which arise 
through random mutagenesis, to escape preexisting population immunity, termed genetic 
drift. A more drastic change in circulating strains can occur when two strains co-infect a 
single cell and give arise to recombinants that have a mix of the viral RNA from the two 
viruses, termed genetic shift. Genetic drift is one reason why we require annual 
vaccination while genetic shift can give rise to potential pandemic strains for which few 
in the population have immunity against, such as happened in 1918 and 2009 (100). 
Antivirals also exist that help decrease the severity and duration of disease but they must 
be administered very early during infection in order to be efficacious and resistance 
easily arises against these drugs [reviewed in (48)]. The two classes of antiviral 
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medications are the neuraminidase inhibitors, Oseltamivir and Zanamivir, and M2 
inhibitors, Rimantadine and Amantadine. 
 Due to the threat of future pandemics, the unpredictability of which influenza 
strains will circulate in a given year, and the existence of resistance to all current 
influenza antivirals, continued research on the basic viriology of influenza A virus is 
warranted. 
 
Assembly of Infectious Virus and Virus-Like Particles 
 There are at least four different types of enveloped viral products that can be 
assembled and released from the plasma membrane of host cells, virus-like particles 
(VLPs), pseudotyped VLPs, pseudotyped virus particles, and infectious virus particles. 
Enveloped VLPs are characterized by a cell membrane derived envelope that 
incorporates at least one viral glycoprotein or internal structural protein (Fig 1A). If any 
viral genetic material is present, it is either incomplete or artificial; therefore, VLPs are 
non-replicating. Pseudotyped VLPs are generated by the co-expression of glycoproteins 
from one or more viruses along with the internal core proteins from a different host virus 
(Fig 1B). Like VLPs, the genetic material in pseudotyped VLPs is either incomplete or 
artificial, if present at all, and the particles are non-replicating. Pseudotyped virus 
particles are generated by the co-expression of glycoproteins from one or more viruses in 
cells infected by another virus that either has a complete complement of genes or does 
not encode its own glycoproteins (Fig 1C). The potential infectivity of pseudotyped virus 
particles depends on whether the host virus used to infect the cells is fully replication 
competent. Often host viruses are utilized that contain genetic deletions in order to 
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produce particles that cannot replicate. If pseudotyped virus particles are non-replicating, 
they might also be termed pseudotyped VLPs. However, for the purpose of this thesis, 
when the foreign glycoprotein is expressed in trans and not from the viral genome of the 
parent VLP, the particles can never replicate and we term them pseudotyped VLPs. 
Whereas pseudotyped particles formed when the host viral genome is engineered to 
express a foreign glycoprotein will be termed pseudotyped virus particles even if they are 
unable to replicate. Infectious virus particles, unlike VLPs and pseudotyped VLPs, 
contain a complete viral genome and complement of structural proteins, all from the same 
virus (Fig 1D). The differences between these four distinct viral particles will be 
illustrated using vesicular stomatitis virus (VSV), human immunodeficiency virus (HIV), 
and finally influenza A virus. 
 
Virus-Like Particles 
The expression of viral glycoproteins or internal proteins is often sufficient to 
induce the release of enveloped particles from the surface of cells. Despite lacking a 
complete viral genome and, sometimes, the internal structural proteins, VLPs often retain 
similar morphology to infectious virus particles. However, the lack of expression of one 
or more internal proteins can alter packaging organization and result in particles with 
larger diameters or more pleiotropic morphology than those of infectious virus particles 
(123). Due to their lack of a complete viral genome, VLPs are non-replicating. They can 
be generated by transient expression of one or more of the structural proteins. Several 
techniques used for expression include transfection of mammalian expression vectors, 
infection with a recombinant vaccinia virus encoding a T7 bacteriophage polymerase 
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(vvT7) and transfection with a T7 polymerase-driven expression vector, transfection with 
an alphavirus replicon which encodes one or more structural proteins from another virus, 
or infection with an unrelated virus, such an alphavirus or a baculovirus, which has been 
engineered to express one or more structural proteins from another virus. VLPs are used 
to study the role of various viral proteins in virus attachment, fusion, and assembly. They 
have also been safely used as vaccines in animals and humans. 
Vesicular Stomatitis Virus (VSV) VLPs 
 One VSV VLP system is characterized by the expression of the vesicular 
stomatitis virus G glycoprotein (VSV-G) from a Semliki Forest virus (SFV) replicon 
(123). In this system, VSV-G is sufficient to induce VLP formation and the SFV replicon 
gets incorporated into the VLPs randomly. However, the envelopes of VLPs are derived 
from the host, and host proteins may be involved in the release of VLPs. Therefore, the 
choice of host can greatly affect the production and composition of these particles. VSV-
G VLPs are cell system dependent because the system produces VLPs well in BHK, 
CHO, and C6/36 cells, less well in NRK and COS cells, and not at all in HeLa cells 
(123). This system, although able to replicate, is considered a VLP here because only the 
viral glycoprotein is expressed. However, it could, more accurately, be considered a 
simple manmade virus. A modification of this system, to generate replication 
incompetent VSV VLPs, expresses the VSV-G from a plasmid that is co-transfected 
along with the SFV replicon which expresses another gene of interest (24). The latter 
system avoids the overproduction of the cytotoxic VSV-G protein in cells infected with 
the VSV VLPs and could enable use of this technology as a transduction vector. 
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 The matrix protein from VSV (VSV-M) has also been shown to be sufficient 
when expressed alone to induce VLP formation in Sf9 insect cells using a baculovirus 
expression system (82) and in CV1 cells using a vvT7 infection/transfection system (64). 
HIV VLPs 
 The core structure of HIV is encoded by the gag gene which is translated as a 
precursor polyprotein, Pr55gag (MA-CA-NC-p6), which is processed during or after virus 
particle budding by the protease (PR) protein encoded by the viral pol gene to form, from 
N-terminus to C-terminus, the major core proteins matrix (MA), capsid (CA), 
nucleocapsid (NC), and p6. Expression of uncleaved Pr55gag alone using a baculovirus 
expression system is sufficient to form VLPs in Sf9 cells (38). Pr55gag is myristylated at 
the N-terminal glycine residue in MA and induces budding from a type of membrane 
microdomain enriched in cholesterol, glycosphingolipids, and sphingomyelin [(108), 
reviewed in (152)], often called lipid rafts [reviewed in (136)]. Pr55gag has two modes of 
membrane binding [reviewed in (20)]. If the myristylation site is mutated (38) or 
myristylation is chemically inhibited (97), Pr55gag fails to bind membranes and induce 
VLP release, but instead forms circular structures in the cytoplasm and/or nucleus. 
However, a basic patch on MA of Pr55gag is also important for membrane binding and 
directs interactions with acidic phospholipids, particularly phosphatidylinositol 3,4-
bisphosphate [PI(3,4)P2] (19, 107, 141, 164). Unlike membrane binding, p6 is not 
required for virus-like particle formation and release (52, 127). However, expression of a 
MA-CA construct without NC and p6 results in long tubular structures attached to cells 
(38, 52) or a vastly decreased number of spherical particles attached to cells (127). CA-
NC and CA-NC-p6 can form protein cylinders (13) and MA-CA-NC and MA-CA-NC-p6 
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(Pr55gag) can form spheres (12) in vitro in the presence of nucleic acid and in the absence 
of myristylation and phospholipids. This suggests that nucleic acid is important for HIV 
VLP formation and that it can occur with only expression of Pr55gag. Addtionally, Env 
expression does not increase release of particles (38). 
 Strategies utilizing HIV VLPs in attempts to generate an HIV vaccine are too 
numerous to exhaustively describe here [reviewed in (161)]. However, one interesting 
example that has undergone human clinical trials in various forms includes the expression 
of Gag, Env, and PR from a canarypox vaccine (28, 91). Infection of mammalian cells 
with canarypox virsues is abortive and results in only one round of infection. During this 
one round of infection, expression of the HIV proteins leads to the release of VLPs which 
are able to generate CTL responses in some individuals [reviewed in (91)]. 
Influenza Virus VLPs 
 Like VSV, formation of influenza virus VLPs are affected by the host and 
expression system utilized. For instance, Cos-1, CV-1, and HeLa cells expressing 
influenza matrix protein (M1) via a vvT7 infection/transfection system (17, 40) and Sf9 
cells expressing M1 using a baculovirus expression system produce VLPs (68, 77, 117, 
140) (Fig 2A) while BHK cells expressing M1 via a semliki forest virus (an alphavirus) 
replicon do not result in VLP production (163). In the latter example, 3 hours post 
transfection was the latest time point investigated, and it is possible that VLPs might have 
been detected at later time points. Others have shown that in 293T cells, expression of 
either M1 or the proton channel matrix 2 protein (M2) alone by mammalian expression 
vectors results in the production of VLPs (Fig 2A and B), but co-expression of the 
glycoprotein neuraminidase (NA) or both the glycoproteins hemagglutinin (HA) and NA 
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together increases the number of VLPs produced (17, 76). Additionally, the level of M1, 
but not HA or NA, expression, has also been shown to be correlated with the level of 
VLP production when measured by the incorporation of a reporter gene (102). 
Correlation of M1 and reporter gene levels may relate to the role of M1 during genome 
packaging. 
It has been reported that expression of HA alone is insufficient to produce VLPs 
(77). However, these experiments do not take into account that, during both viral entry 
and egress, HA binds sialic acid and will result in retention or clumping of budded VLPs 
and virus particles unless sialidase activity is present either in a co-expressed NA or in 
exogenously added NA (17, 41, 83, 110). In fact, several reports have now shown that 
expression of HA alone can produce VLPs when an NA is added exogenously (17, 76) 
(Fig 2C). Additionally, both insect and plant cells, which usually do not produce proteins 
containing terminal sialic acid resides (90, 134), can also be used to produce HA 
containing VLPs in the absence of NA (23, 32, 33, 45, 72, 117, 119).  
Recently, several groups have investigated the ability of NA to induce VLPs in 
the absence of the other viral proteins. Expression of some strains of NA alone are able to 
induce VLP formation while others are not (76, 77, 160) (Fig 2D). 
All of these studies taken together show that in various systems, the expression of 
M1, M2, HA, or NA alone is sufficient to produce influenza A virus VLPs (Fig 2). 
Differences in the expression systems and cellular hosts may account for why each 
system shows that a different protein is necessary and sufficient for VLP formation. 
Assembly and release of VLPs is highly dependent on cellular processes like expression 
levels and locations, glycosylation, vesicular sorting, and trafficking. Each cell system 
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may have slight differences in these or other cellular processes which are required for, 
contribute to, or restrict the production of VLPs. 
 Influenza virus VLPs have been used to successfully induce protective 
immunological responses in animals [reviewed in (67)] when expressing M1 and M2 (Fig 
2E) (139, 140), HA and M1 (Fig 2F) (32, 33, 68, 72, 117, 119, 138), M1, HA, and NA 
(Fig 2G) (3, 4, 88, 115, 116, 144), M1, HA, NA, and M2 (Fig 2H) (93, 158), and all viral 
proteins minus NS2/NEP (154), but not M1 alone (140). Influenza virus VLPs expressing 
HA, NA, and M1 are currently moving through human clinical trials (70). Influenza virus 
VLPs and inactivated vaccines can both be multivalent (29, 114, 119). VLPs have also 
been considered as a supplement to inactivated vaccines in an attempt to broaden the 
cross protection (139) and have been utilized as a carrier to present foreign glycoproteins 
which will be discussed below as pseudotyped VLPs. 
 
Pseudotyped Virus-Like Particles 
Pseudotyped VLPs are produced like VLPs except that one or more glycoproteins 
are co-expressed from a different virus. There are two advantages to generating 
pseudotyped VLPs. One is if the glycoprotein of interest does not induce VLP formation, 
then core proteins from a virus known to induce VLPs can be used to generate 
pseudotyped VLPs that incorporate the glycoprotein of interest. A second purpose is that 
VLPs from a characterized system can used to quickly generate new ones that express a 
glycoprotein from another virus without the development of new characterization or 
purification protocols. The simultaneous expression of glycoproteins from one or more 
viruses along with the internal proteins from another virus has been achieved via several 
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mechanisms. The glycoproteins from one virus can be co-expressed with the internal 
proteins from another virus using mammalian expression vectors. Pseudotyped virus 
particles can also be generated by the expression of the glycoproteins using expression 
vectors followed by infection with a virus that does not encode its own glycoproteins. 
Like VLPs, pseudotyped virus particles have been used to study the role of various viral 
proteins during virus attachment, fusion, and assembly and are being utilized to generate 
vaccines that elicit immune responses to the glycoproteins. 
Pseudotyped VSV VLPs 
 Whereas, the expression of influenza matrix (M1) protein has been used as a 
means of generating VLPs that can also incorporate glycoproteins from foreign viruses, 
VSV matrix (VSV-M) VLPs have not been utilized in the same way, perhaps because 
less research has been conducted on them. Nonetheless, non-replicating VSV particles 
have been engineered from a recombinant VSV which has its own glycoprotein deleted 
(VSVΔG) (143). In situations where the glycoprotein is provided in trans from another 
expression system, VSV pseudotyped VLPs have been formed using glycoproteins from 
several viruses including influenza C virus (47), measles virus (145), SARS coronavirus 
(31), Hantaan and Seoul viruses (105), HBV (128), Andes virus (120), Nipah virus (98), 
Ebola virus (143), and human T-cell leukemia virus 1 (106). 
 Due to the relative safety and easy creation of pseudotyped VSV VLPs, they have 
been used in virus entry studies of Andes virus (120), Nipah virus (98), Ebola virus (143), 
and human T-cell leukemia virus 1 (106), and measles virus (145) as well as effective 
vaccines in animal models for Hantaan and Seoul viruses (78). 
Pseudotyped HIV VLPs 
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 HIV VLPs are easily generated from expression of Gag alone, see above, and 
these VLPs can also be pseudotyped with foreign glycoproteins. Generation of 
pseudotyped HIV VLPs has been successfully used to generate protective immunity 
against influenza virus (51). Additionally, HIV VLPs pseudotyped with influenza HA 
(159) and VSV-G (74) have been used in attempts to generate immunity against HIV Gag 
in the absence of the immunodominant HIV Env. HIV VLPs co-expressing both HIV Env 
and other additional glycoproteins have also been utilized in an attempt to boost the 
immune response to Env (45).  
Pseudotyped Influenza VLPs 
 Influenza VLPs can be pseudotyped when VSV-G is co-expressed with either 
PB2, PB1, PA, NP, M1, M2, and NS2 (102) or NA, M1, and M2 (77). However, both of 
these systems are fairly complex and have not been studied further. Simple pseudotyped 
VLP systems are preferred that only require matrix from one virus and glycoproteins 
from another. Indeed, influenza VLPs can be generated from the individual expression 
of M1 protein, see above. Although some debate in the field on whether M1 was 
sufficient has hindered until recently the generation and use of pseudotyped influenza 
VLPs. Co-expression of viral glycoproteins from other viruses, along with M1, can result 
in their incorporation into the VLPs. When the transmembrane domain and cytoplasmic 
tails of the spike glycoprotein from SARS coronavirus is replaced with that from 
influenza HA, it can be successfully incorporated into influenza M1 VLPs and 
administration in the absence of adjuvant protects mice better than purified spike protein 
(Fig 3A) (84). Recently, respiratory syncytial virus (RSV) F and G glycoproteins were 
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both successfully pseudotyped onto influenza VLPs and were both able to induce some 
protective immunity in mice (Fig 3B) (118).  
 
Pseudotyped Virus Particles 
Pseudotyped (or chimeric) virus particles are produced when a glycoprotein from 
one virus (glycoprotein donor) is expressed in cells that are infected with another virus 
(core donor). The two donor viruses can be from completely different viral families or 
simply different strains of the same virus. The core donor can express its own 
glycoproteins or can be engineered not to express its own surface proteins. The 
expression of donor glycoprotein(s) can be accomplished using several techniques 
including transfection with cDNA expression vectors, co-infection with either the donor 
virus or an unrelated virus expressing donor glycoprotein, or a recombinant core donor 
virus can be engineered to express the donor glycoprotein in addition to or in place of its 
own glycoprotein(s). 
Pseudotyped VSV Virus Particles 
 A strain of VSV encoding a temperature sensitive (ts) mutation in the 
glycoprotein G has been used to study the ability of glycoproteins from various other 
viruses to incorporate into budding particles (30). Rabies virus glycoprotein G was shown 
to incorporate into this ts VSV and mediate subsequent infection which could be blocked 
by antibodies against rabies G but not VSV-G (155). Co-expression of a fusion of HIV 
Env with the cytoplasmic tail of VSV-G, but not of full length HIV Env, can also be 
incorporated into this ts VSV when it buds, suggesting that amino acids in the 
cytoplasmic tail of VSV-G may interact with matrix and drive incorporation (109, 156). 
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Indeed, native Moloney murine leukemia virus (MuLV) glycoprotein is unable to be 
incorporated into this ts VSV at non-permissive temperatures (157). The ability to form 
rabies G pseudotyped VSV VLPs may relate to the fact that rabies virus and VSV are 
both rhabdoviruses and their glycoproteins might share enough sequence homology that 
the cytoplasmic tail of rabies G can interact with VSV-M sufficiently to incorporate it 
into budding virus particles. 
 VSV pseudotypes that incorporate VSV-G as well as a foreign viral glycoprotein 
have been generated by the co-infection of VSV and many other viruses including 
influenza A virus (126), MuLV (157), visna virus (39), lymphocytic choriomeningitis 
virus (9), HIV (124), and human T-cell leukemia viruses (21). However, distinguishing 
between the two types of virus particles, VSV genome/core or foreign virus genome/core, 
can be quite difficult and limits the usefulness of pseudotyped virus particles generated 
from co-infections. 
 The genome of VSV can be engineered to encode extra genetic material and this 
has been utilized as a mechanism to express foreign proteins (132). HIV Gag and Env 
expressed this way generate their own HIV VLPs but do not get incorporated into the 
VSV particles, and therefore do not form VSV pseudotyped virus particles (46). The lack 
of incorporation of Env into VSV virus particles could be due to an inherent 
incompatibility between the Env and VSV matrix since Env incorporation into VSV can 
be induced by deleting three residues from its cytoplasmic tail or replacing the tail with 
the VSV-G cytoplasmic tail (62, 63). Similarly, VSV which encodes core, E1, and E2 
from hepatitis C virus (HCV) seems to release HCV VLPs but no HCV-pseudotyped 
VSV virus particles (2, 26). Like HIV Env, HCV glycoproteins E1 and E2 can be 
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incorporated into VSV virus particles by alteration of the cytoplasmic tail, which 
removes the ER retention motifs in E1 and E2 (75, 94). Additionally, other full length 
viral glycoproteins are able to be incorporated into the wildtype VSV virus particles 
including cellular CD4 (131), H and F of measles virus (131), F and G from RSV (66), 
GP from Ebola, Marbug, and Lassa viruses (35), and HA and NA from influenza A virus 
(73). 
 More recently, reverse genetics have been used to generate recombinant VSV that 
does not encode VSV-G (143). This VSVΔG virus can be generated in cells expressing 
VSV-G and when used to infect cells expressing a foreign glycoprotein in trans, non-
replicating pseudotyped VSV VLPs are generated (see above). However, this VSVΔG 
can also be engineered to express a foreign glycoprotein in cis by cloning the 
glycoprotein into the VSV genome, which generates pseudotyped VSV virus particles. 
As long as cells which express the receptor to the foreign glycoproteins are infected, then 
the pseudotyped virus particles are able to replicate and produce new pseudotyped virus 
particles. This system has been developed for several diverse viruses including influenza 
A virus (121), HCV (10), Ebola, Marburg, and Lassa viruses (35), and RSV (65). 
 Pseudotyped virus particles, have been used as effective vaccines in animal 
models when core proteins and genetic material from VSV are encased in lipid 
membranes containing glycoproteins from other viruses, including Ebola, Marburg, and 
Lassa viruses [(35), reviewed in (27)], as well as Nipah virus (14), HCV (89), and RSV 
(65). 
Pseudotyped Influenza Virus Particles 
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 Before the creation of an influenza A virus reverse genetic system, reassortment 
of two strains of influenza was used as a mechanism of studying individual genes as well 
as a way to generate the yearly vaccine candidates. A reassortant virus that expresses HA 
and/or NA from one strain and the core proteins from another strain is essentially a 
pseudotyped virus particle. Since influenza A viruses contain 8 genomic segments, a co-
infection with two strains could result in 28 or 256 different possible strains. Reverse 
genetics has greatly improved the ability of obtaining a virus that encodes glycoproteins 
one strain and all other segments from another strain, often referred to as a master donor 
strain (Fig 4). 
 Pseudotyping influenza virus particles is the primary method used every year to 
generate both the live attenuated and inactivated annual seasonal influenza vaccines 
[reviewed in (29)]. The inactivated seasonal vaccine is currently generated using a 
reverse genetics system in which the HA and NA genes from the strains predicted to 
circulate in the upcoming influenza season are combined with the 6 other segments from 
a high growth donor strain adapted to grow to high titers in eggs, A/Puerto Rico/8/34 
(PR8). Likewise, the live attenuated seasonal vaccine is generated using similar 
methodology with the exception that the donor strain which provides all segments other 
than HA and NA is a cold-adapted, live attenuated strain, A/Ann Arbor/6/60. 
 
Infectious Virus Particles 
Infectious virus particles can enter a cell and generate infectious, and sometime 
non-infectious, progeny. They are normally generated by the infection of cells with live 
virus, but they can also be initially generated several other ways. With many positive 
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stranded RNA viruses, transfection of RNA or expression of the RNA from a plasmid can 
result in production of infectious virus particles. Reverse genetic systems also exist for 
many negative sense RNA viruses where infectious virus can be produced from the 
expression of the polymerase genes, either by mammalian expression vectors or non-
replicating helper viruses, along with negative sense viral RNA, either by RNA 
transfection or plasmid expression of the viral RNA using polymerase I promoter and 
terminators in order to generate ribosomal RNA that lacks both 5’ cap and a 4’ poly(A) 
tail (25, 101, 103). 
Infectious VSV Virus Particles 
 Another virus that assembles with a two step process is VSV. However, this 
process is different from influenza virus in that both steps, RNA incorporation and 
particle formation/release, are directed by one protein, VSV-M. The assembly and 
budding of VSV has been studied extensively [some reviewed in (60)]. After 
transcription and replication of the single segment of VSV vRNA, the vRNA is bound 
and protected by the VSV-N protein to form a ribonucleoprotein complex (RNP) (44, 
147). The VSV-M protein has inherent membrane binding capabilities and exists as two 
pools in cells, one in the cytoplasm and one at the plasma membrane (79). Membrane 
binding by VSV-M can induce membrane curvature and is the only viral protein required 
for particle release, see above, but it is insufficient to induce complete budding in the 
absence of cellular proteins (137). The binding of VSV-M to the RNPs induces 
condensation and formation of the skeleton structure that is found in viral particles (69, 
87, 104). This VSV-M interaction with RNPs may be seeded by the presence of the 
glycoprotein G (142). Indeed, cryo-electron microscopy models of N-M complexes 
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suggest that VSV-N forms the tip of the bullet-shaped viral particle and is only 
surrounded and strengthened by VSV-M (37). However, this condensation, incorporation, 
and release of particles has been shown in the absence of the glycoprotein G (143). As 
was previously noted, expression of M alone can lead to production of VLPs, further 
suggesting that VSV-G is not required for production of virus. However, in the absence 
of VSV-G, the budding “bald” particles are unable to bind, enter, and infect subsequent 
cells since VSV-G is responsible for viral attachment and fusion (143). 
VSV buds from microdomains at the plasma membrane which are enriched in the 
glycoprotein G (6, 85, 86). Influenza microdomains are similar to lipid rafts in that they 
are in enriched in cholesterol, gangliosides glycosphingolipids, and GPI-anchored 
proteins and can be extracted due to their low solubility in cold non-ionic detergents such 
as TX-100 [reviewed in (136)], whereas VSV microdomains are thought to be 
independent of both lipid rafts and CD4-containing microdomains (5, 7). In fact, VSV-G 
is often used as a negative control for lipid rafts (162). 
VSV-M contains two late motifs [reviewed in (11)], a PPxY late motif, which is 
important for virus particle release, interacts with WW domain containing proteins like 
Nedd4 (22, 49, 50, 61) and a PSAP late motif that does not appear to be important for 
virus particle release (58). 
As discussed previously, expression of VSV-G alone, like VSV-M, is sufficient to 
induce VLP formation; however, non-infectious virus particles can form in the absence of 
G albeit less efficiently (143). Although there are not specific interactions between the 
VSV-G cytoplasmic tail and VSV-M (130), VSV-G is nonetheless believed to enhance 
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the ability of VSV-M to bind and condense RNPs, thereby slightly enhancing particle 
release in the presence of VSV-G (60, 130, 142). 
Infectious HIV Virus Particles 
 HIV assembly and budding occurs in two steps like VSV. However, for HIV, the 
first step involves RNA packaging, as well as virus assembly and release, and the second 
step involves maturation of the particles. HIV budding is largely driven by Pr55gag, see 
above, and the localization of Pr55gag in particular membrane microdomains drives virus 
particle assembly and budding from these locations. Therefore, like influenza, VSV, and 
many other viruses, HIV buds from a type of membrane microdomains often called lipid 
rafts which are enriched in cholesterol, glycosphingolipids, and sphingomyelin [reviewed 
in (136, 152)]. Also, similar to influenza, tetraspanins get incorporated into HIV virus 
particles and but their role in virus budding is unclear [reviewed in (146)]. 
 In a simplified model of HIV budding, MA directs membrane binding, CA assists 
Gag-Gag interactions, NC binds viral RNA, and p6 recruits cellular factors involved in 
particle release [reviewed in (34)]. It should be stated that most of these functions of the 
Gag proteins are occurring while Pr55gag is uncleaved and, therefore, multiple Gag 
domains interact in a highly complex way in order to direct and control the various 
budding processes including membrane and RNA binding, oligomerization, and particle 
release. 
 During virus particle release, protease (PR) is activated and cleaves Pr55gag inside 
immature particles into several proteins, including matrix (MA), capsid (CA), 
nucleocapsid (NC), and p6 [reviewed in (34)]. This cleavage causes structural 
rearrangement inside the virion, often called maturation, resulting in the formation of 
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infectious, mature particles. After this structural rearrangement there are three distinct 
layers inside the viral membrane; MA remains bound to the inside leaflet of the viral 
membrane forming an electron dense ring, CA assembles into a conical capsid that sits 
inside the MA layer, and NC coats the vRNA and resides in the center of the virions. 
Although MA-CA-NC, without p6, can induce VLP formation (see above), p6, in 
particular a PTAP late domain within the protein, is required for efficient virus particle 
release in the context of virus infection (42, 53). Particles can be released in the absence 
of this late domain within p6 if the protease activity of PR is disrupted; however, particles 
that bud in this fashion never undergo proteolytic maturation of Pr55gag and are non-
infectious (53). The late domain in p6 has been shown to mimic the cellular Hrs protein 
in order to bind TSG101, a cellular component of ESCRT-I complex which normally aids 
in the cellular vesicle protein sorting pathway, and co-opt it into helping release HIV 
virus particles [(36, 92, 113), reviewed in (11)]. 
 The release of HIV virus particles can be restricted by a cellular protein, tetherin, 
which can bind both the plasma membrane and the viral membrane and prevent particles 
that have undergone scission from being released into the supernatant (99, 151). The 
activity of tetherin can be modulated by the HIV protein Vpu which downregulates the 
surface expression level of tetherin (99, 151). 
 Like influenza virus and VSV, HIV virus particles can bud in the absence of 
glycoprotein Env expression. However, whereas specific interactions between the matrix 
and glycoproteins of the former two viruses have been shown to various extents, 
interactions between HIV Env and Gag have never been conclusively proven [reviewed 
in (152)]. An interesting model put forth recently based on Ebola pseudotyping of HIV in 
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the presence of Env co-expression is that microdomains containing Gag interact with 
distinct microdomains containing different glycoproteins thus producing particles with 
either HIV Env or Ebola glycoprotein but not both (81). This study suggests that 
incorporation of glycoproteins into HIV virus particles may rely more on aggregation of 
membrane microdomains rather than direct interactions between Gag and they 
glycoproteins. 
Infectious Influenza Virus Particles 
 The assembly of influenza virus particles occurs at microdomains in the plasma 
membrane which are enriched in the viral glycoproteins, HA and NA. These 
microdomains contain an enrichment of cholesterol and resemble lipid rafts [(80, 129, 
162), reviewed in (136)]. M1 interacts with the HA and NA in these sites, potentially 
through their cytoplasmic tails (1, 162). M2 is then recruited to the budding site and is 
important for viral RNA incorporation (16, 43, 95, 96). The mechanism of M2 
recruitment and incorporation is currently under debate. Several potential methods of M2 
incorporation have been suggested including ectodomain binding (112), cholesterol 
binding (133), and interactions with M1 (16, 95). However, there remain a few issues 
with these proposed incorporation mechanisms. The work by Park et al. describing that 
the ectodomain of M2 is sufficient to drive incorporation was based upon chimeras 
between M2 and the Sendai F protein (112). Because Sendai F has a structure very 
different from M2 and many of these chimeras were not expressed at the cell surface, 
complete interpretation of the findings is difficult. No research following up this claim 
has been published and there are no known interactions between the ectodomains of M2 
and the other viral glycoproteins, HA and NA. Schroeder et al. first published that 
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cholesterol can bind M2 in vitro and suggested that binding cholesterol that rims the 
microdomains where assembly occur could induce M2 incorporation (133). The 
remaining hypothesis, interactions between M1 and M2 drive the incorporation of M2, 
has been studied but is not yet definitive. Two M1 binding sites within the M2 
cytoplasmic tail have been mapped, one in the membrane proximal region (residues 45-
69) and another in the membrane distal region (residues 70-97) (95, 96). Deletion or 
mutation of amino acids in the membrane distal region lead to decreased vRNA 
incorporation but do not affect M2 incorporation (16, 43, 95, 96). The mechanism of M2 
incorporation and the role the membrane proximal region of the cytoplasmic tail in this 
process are the focus of this thesis. 
 The M2 protein and a peptide corresponding to an amphipathic helix in the 
membrane proximal cytoplasmic tail of the protein, have also been shown to induce 
membrane curvature and scission in unilamellar vesicles and were suggested to be 
necessary for membrane scission and virus particle release (125). However, both VLPs 
(16, 17, 40, 68, 76, 77, 117, 140, 150, 160), as discussed above, and virus particles (18, 
43, 57) can be released in the absence of M2. 
Despite release of virus particles occurring in the absence of M2, various 
deletions and mutations in M2, and in particular the cytoplasmic tail, attenuate virus 
replication significantly (43, 59, 95, 96) and can be complemented with full length M2 
expressed in trans (16, 43, 95, 96). Thus influenza A virus assembly and budding can be 
described as two types or steps, similarly to VSV and HIV. Indeed, if M2 is not 
expressed, virus particles are assembled and released, but they have a defect in vRNA 
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incorporation (Fig 5A) (43). Infectious virus particles are only produced when functional 
M2 is expressed and incorporated into the budding particles (Fig 5B) (16, 43, 95, 96). 
During virus budding, viral proteins through late domains have often been shown 
to redirect cellular proteins to the assembly site to achieve scission [reviewed in (15)]. 
The sequence YRKL in M1 was proposed as a late domain, but much of that work has 
subsequently been retracted (54-56). Additional support that M1 might not contain a viral 
late domain comes from the findings that budding of influenza virus particles, as well as 
influenza VLPs, have been shown to be VPS4 independent, unlike other viruses which 
utilize late domains (8, 17). 
Numerous cellular proteins are known to be required for replication, assembly, 
and release of influenza A virus. A genome-wide RNAi screen identified that, among 
other cellular proteins, a cellular tetraspanin protein, CD81, was necessary for influenza 
virus replication (71). Both CD81 and tetraspanin CD9 have also been identified in 
purified influenza virus particles (135). However, further research will be required to 
identify how CD81 and possibly other tetraspanins are necessary for virus replication. 
Another cellular factor that affects the budding of various viruses is tetherin. However, 
the ability of tetherin to restrict influenza budding has not yet been fully elucidated. The 
budding of VLPs containing only NA is tetherin restricted in one strain of influenza virus 
but not another (160). However, a recent report suggested that infectious influenza virus 
particles expressing tetherin-restricted NA are not themselves restricted by tetherin (153). 
It may very well turn out that some influenza VLPs but not influenza virus can be 
restricted by tetherin, but in the latter paper, the assays used to compare virus and VLP 
restriction were completely different, stable expression of tetherin in MDCK cells or 
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transient over-expression in 293T cells, respectively. Additionally, electron micrographs 
of infected 293T cells clearly show elongated viral particles when tetherin is transiently 
expressed, a defect not seen when other viruses are restricted by tetherin. Nonetheless, 
this suggests that transient tetherin expression in 293Ts can restrict influenza virus and 
influenza VLPs. However, more work needs to be done to clearly elucidate which, if any, 
strains of influenza virus are restricted by tetherin during infection or VLP formation. 
Additional experiments should also determine the average length of influenza virus 
particles released from 293T cells in the presence and absence of tetherin. 
 
Concluding Remarks 
Non-enveloped VLPs 
 Although this discussion has focused on enveloped particles, it is noteworthy that 
VLPs can also be produced by the expression of proteins from non-enveloped viruses. 
Two licensed, VLP-based human papillomavirus vaccines are on the market, Cervarix 
from GlaxoSmithKline and Gardasil from Merck, which are produced from the 
expression of L1 from baculovirus and yeast cells, respectively [reviewed in (111)]. 
Expression of some enveloped virus capsid proteins can also generate non-enveloped 
VLPs. Natural infection with hepatitis B virus (HBV) results in the production of subviral 
particles (essentially VLPs) which can be used to generate protective immune responses. 
Recombinant versions of HBV VLPs are currently licensed by several manufacturers 
[reviewed in (122)]. 
Summary of VLPs and Infectious Virus Particles 
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The differences between VLPs, pseudotyped VLPs, pseudotyped virus particles, 
and infectious virus particles have been carefully defined in this review. However, the 
literature sometimes uses some of the terms interchangeably. Nonetheless, VLPs remain 
a valuable tool for dissecting virus biology, but results found with them should always be 
confirmed in the context of infectious virus particles. Pseudotypes, in particular 
pseudotyped VLPs, remain promising vaccine platforms. Similarities and differences 
between infectious virus particles will continue to be revealed. 
 
Goals of the Thesis 
 The primary aim of this thesis was to determine the role of the membrane 
proximal region of the M2 cytoplasmic tail in virus replication. It was known previously 
that this region was able to bind M1 (95), was able to bind cholesterol in vitro (133), and 
that deletion of the rest of the M2 cytoplasmic tail still allowed incorporation of M2 (96). 
Through a series of experiments that I proposed, I sought to investigate the various 
aspects of the membrane proximal region of M2. Mutant proteins were investigated using 
mammalian expression systems, a trans-complementation system, and recombinant 
viruses. I determined that the M2 cholesterol binding motif is not required for virus 
replication in tissue culture but viruses lacking the motif caused less morbidity and 
mortality in mice. I additionally established that the membrane proximal residues 
tolerated numerous mutations with little, if any, affect on virus replication suggesting that 
the protein structure of this region, rather than the identity of individual amino acids, may 
be critical for M2 protein function. Chimeric proteins between influenza A virus M2 and 
an M2 homolog in influenza C virus, CM2, were also utilized to compare the ion channel 
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function of the two proteins. I further confirmed that residues in the ectodomain and 
cytoplasmic tail of M2 are important in the assembly of infectious influenza A virus. 
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Figure Legends 
 
Figure 1. Composition of various enveloped particles produced by the expression of 
viral proteins. A) The expression of viral glycoproteins and/or internal core proteins can 
induce the formation of virus-like particles (VLPs). B) The co-expression of 
glycoproteins from one or more distinct viruses during the production of VLPs from 
another virus can produce pseudotyped virus-like particles which may contain 
glycoproteins and/or core proteins from one virus along with glycoproteins from other 
viruses. C) Pseudotyped virus particles are produced by the co-expression of 
glycoproteins from distinct viruses in cells infected with another virus. D) Infectious 
virus particles are the product of natural virus infections and are characterized by a 
complete viral genome and complement of viral proteins. Natural infections can 
sometimes also produce incomplete virus particles that are non-infectious, not shown. In 
pseudotypes, foreign glycoproteins are shown in blue and yellow and, in all particles, 
proteins from the parental virus are shown in red. 
 
Figure 2. Influenza virus-like particles (VLPs). A-D) Depending on the particular 
expression system and strain of influenza A virus, M1 (A), M2 (B), HA (C), or NA (D) 
expression alone has been shown to be sufficient to induce VLP budding and release. E-
H) Various influenza A VLPs which have been shown to induce various levels of protect 
immunity in immunized animals include ones generated from the expression of M1 and 
M2 (A); M1 and HA (B); M1, HA, and NA (C); and M1, HA, NA, and M2 (D). 
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Figure 3. Pseudotyped influenza VLPs. Foreign glycoproteins can be incorporated into 
influenza VLPs when co-expressed with M1 using a baculovirus expression system. A) 
The ectodomain of SARS coronavirus spike (S) protein fused to the transmembrane 
domain and cytoplasmic tail of influenza HA and B) the native glycoproteins G and F 
from RSV can be incorporated into influenza VLPs 
 
Figure 4. Pseudotyped influenza virus particles. Pseudotyping influenza viruses is 
utilized to generate influenza vaccines candidates. Either by co-infection or reverse 
genetics, the HA and NA glycoproteins from a glycoprotein donor strain are combined 
with all the proteins expressed by the other 6 segments from a core donor strain to 
generate a pseudotyped influenza virus particle. 
 
Figure 5. Infectious influenza virus particles. A) If M2 is not expressed, virus particles 
assembly and are released, but they have a defect in viral RNA (vRNA) incorporation 
and viral infectivity. B) If functional M2 is expressed, infectious virus particles are 
formed that incorporate M2 and vRNA. 
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Figure 2. Influenza virus-like particles (VLPs). 
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Figure 5. Infectious influenza virus particles.  
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The cholesterol recognition/interaction amino acid consensus motif of the influenza 
A virus M2 protein is not required for virus replication but contributes to virulence 
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Abstract  
Influenza A virus particles assemble and bud from plasma membrane domains enriched 
with the viral glycoproteins but only a small fraction of the total M2 protein is 
incorporated into virus particles when compared to the other viral glycoproteins. A 
membrane proximal cholesterol recognition/interaction amino acid consensus (CRAC) 
motif was previously identified in M2 and suggested to play a role in protein function. 
We investigated the importance of the CRAC motif on virus replication by generating 
recombinant proteins and viruses containing amino acid substitutions in this motif. 
Alteration or completion of the M2 CRAC motif in two different virus strains caused no 
changes in virus replication in vitro. Viruses lacking an M2 CRAC motif had decreased 
morbidity and mortality in the mouse model of infection, suggesting that this motif is a 
virulence determinant which may facilitate virus replication in vivo but is not required for 
basic virus replication in tissue culture.  
60 
 
Introduction 
 Influenza A virus remains a major public health burden and potential pandemic 
threat even with widespread annual vaccination and the availability of antivirals. The M2 
protein is required for several steps in the viral life cycle (reviewed in (28)). Following 
hemagglutinin (HA)-mediated virus-cell membrane fusion, the ion-channel activity of 
M2 is activated in acidified endosomes. M2 translocates protons into the core of the virus 
particle which mediates the release of viral ribonucleoprotein (vRNP) complexes from 
their association with matrix (M1) protein and viral membranes. The vRNP are 
tranported to the nucleus where viral transcription and genome replication occurs. The 
ion-channel activity of M2 also raises the pH of the Golgi compartment, thereby 
preventing the low pH induced conformational changes in HA proteins which are 
processed to their fusion-competent forms by intracellular proteases. Virus particle 
assembly occurs at the plasma membrane and the cytoplasmic tail of M2 is required for 
efficient incorporation of vRNP into infectious virus particles (19, 20). 
 Influenza A virus particles assemble and bud from plasma membrane domains 
enriched with the viral glycoproteins, HA and neuraminidase (NA). These domains may 
also reflect lipid rafts (15, 32, 45). The cytoplasmic tails of HA and NA bind and recruit 
M1 to membranes (1). Even though M2 is not found at these sites of glycoprotein 
enrichment, a small amount of M2 is incorporated into virus particles (15, 45). 
Additionally, the amount of M2 incorporation can be increased if the glycoproteins are 
targeted away from lipid microdomains by the deletion of their cytoplasmic tails (3).  
Several mechanisms have been hypothesized to contribute to M2 virion 
incorporation, including random incorporation and incorporation via interaction with 
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cholesterol (34). A membrane proximal cholesterol recognition/interaction amino acid 
consensus (CRAC) motif has been identified in the peripheral-type benzodiazepine 
receptor and other proteins known to bind cholesterol (16), including caveolin-1 (6) and 
human immunodeficiency virus (HIV) gp41 (8, 39, 40). The CRAC motif in gp41 is 
adjacent to a transmembrane helix and has been shown to bind cholesteryl-hemisuccinate 
agarose (39). Mutation of the motif decreased cholesterol binding but also altered 
fusogenic activity when introduced into HIV (4, 40). Schroeder et al. identified a putative 
CRAC motif in M2 and determined that M2 protein purified from a baculovirus 
expression system binds cholesterol (34). A second CRAC motif immediately 
downstream of the first one is present in a limited number of influenza virus strains. They 
suggest that cholesterol-bound M2 protein may be able to either rim or unite lipid 
microdomains, thereby facilitating M2 incorporation into virions. Because M2 is required 
during several distinct steps in the virus life cycle, we investigated the importance of the 
CRAC motif on virus replication by generating recombinant proteins and viruses 
containing alterations in this motif.  
 
Results  
Oligomerization and expression of mutant M2 proteins in stable cell lines. 
Influenza A/WSN/33 (rWSN) encodes an M2 protein with a consensus (L/V-X(1-5)-Y-X(1-
5)-R/K ) CRAC motif ((13, 14, 16, 17), reviewed in (5)) while A/Udorn/72 (rUd) encodes 
a protein with an R at position 54 which disrupts the consensus (Figure 1). These 
influenza virus strains do not possess a second putative CRAC domain (34).  Mutations 
were made in rWSN M2 to alter the CRAC motif by either mutating residue 54 from 
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arginine to phenylalanine (rWSN M2 R54F), the amino acid found in the  rUd M2 
protein, or changing all of the critical CRAC motif residues to alanine (rWSN M2 
delCRAC) in order to eliminate the consensus sequence. Additionally, the CRAC motif 
in rUd M2 was completed by mutating residue 54 from phenylalanine to arginine (rUd 
M2 F54R). The WSN M2 proteins also contain an asparagine to serine mutation at 
residue 31 which conveys amantadine sensitivity (9, 36) so that the potentially toxic 
effects of ion channel activity could be inhibited during routine cell culture. 
Stably transfected MDCK cell lines were generated which constitutively express 
the wildtype or mutant M2 proteins. Mutation of the CRAC motif does not affect M2 
protein oligomerization as determined by non-reducing SDS-PAGE and Western blotting 
(Fig 2A and D). To determine if the mutant M2 proteins were expressed at the cell 
surface, flow cytometry was performed on live cells using an antibody which recognizes 
the extracellular domain of M2. Greater than 90% of the cells express M2 at the cell 
surface (Fig 2B and E). The total amount of mutant M2 expressed in the stable cell lines 
was comparable to a control cell line expressing wildtype M2 protein (Fig1A and D) as 
was the amount of M2 expressed at the cell surface (data not shown). 
M2 proteins with altered CRAC motifs are able to complement M2 deficient 
viruses. The M2 protein plays several roles in the virus life cycle and altering any of 
these functions can drastically reduce virus replication and fitness (12, 19, 20, 36). The 
ability of stably expressed M2 to complement M2 deficient viruses has been previously 
used to study mutations in M2 which may prevent the rescue of recombinant viruses (2, 
19, 20, 37). To determine if M2 proteins with mutations in the CRAC motif are able to 
complement M2 deficient viruses, stable cell lines expressing M2 were infected with 
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viruses which contain a stop codon in their M2 gene (M2Stop viruses). Neither alteration 
of the CRAC motif (Fig 2C) nor completion of the CRAC motif (Fig 2F) resulted in a 
statistically significant change in the production of infectious virus when compared to wt 
M2, indicating all the mutated M2 proteins are fully functional in this assay. 
Alteration of M2 CRAC motif does not affect the replication of recombinant 
influenza A viruses in tissue culture. In order to confirm that mutation of the CRAC 
motif in the M2 protein does not affect virus replication, recombinant viruses were 
generated which encode M2 proteins with mutations in the CRAC motif (Figure 1). 
Infection of MDCK cells with these viruses results in a similar level of cell surface M2 as 
determined by flow cytometry (Fig 3A and D). Multistep growth curves in MDCK (Fig 
3B and E) and the human lung adenocarcinoma, CaLu-3 cells (Fig 3C and F) results in no 
statistically significant changes in either replication kinetics or peak infectious virus 
titers, indicating the recombinant viruses with altered M2 CRAC motifs maintain the 
ability to replicate in these cell lines. 
Many primary and some laboratory-adapted influenza A virus strains produce 
filamentous particles, including rUd, while most laboratory-adapted influenza A virus 
strains, such as rWSN, produce spherical particles (22, 29, 30). In order to determine if 
completion of the CRAC motif in Ud M2 affects the ability of recombinant virus to 
produce filamentous particles, confocal microscopy was performed to compare the 
number of infected cells which produce filaments. Filaments formed by both rUd M2 
F54R and wildtype were similar in appearance (Fig 4A and B) and the number of 
infected cells showing filaments was not significantly different (Fig 4C). Additionally, 
like wildtype rWSN, rWSN M2 R54F and rWSN M2 delCRAC failed to formed 
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filaments on the surface of infected cells (data not shown). In order to determine if the 
filamentous virus particles were similar in size and structure, transmission electron 
micrographs were taken of infected MDCK cells. The rUd virus encoding M2 F54R was 
able to produce filamentous particles like wildtype virus (Fig 4D and E). Together, this 
data indicates that completion of the CRAC motif does not alter the ability of influenza 
virus to produce filamentous virus particles. 
Virion protein composition of recombinant viruses encoding M2 CRAC 
mutants. In order to investigate the requirement of the CRAC motif for incorporation of 
viral proteins into virions, virus particles were collected and concentrated through a 20% 
sucrose cushion by ultracentrifugation. Virus pellets were resuspended and the amount of 
incorporated viral proteins was determined by Western blot (Fig 5A and B). Relative 
amounts of full length M2 and total M2 were quantified from replicate experiments. Total 
M2 incorporated into either CRAC altered or CRAC completed recombinant viruses was 
not statistically different from wildtype (Fig 5C and D). There was a statistically 
significant decrease in the amount of truncated M2 protein incorporated into rWSN M2 
R54F virions. The truncated form of M2 is thought to be generated via cleavage by 
caspases at the C-terminus of M2 but this cleavage does not appear to affect viral 
replication (46, 47). Additionally, HA, NP, and M1 were incorporated into virus particles 
at levels indistinguishable from wildtype M2when the CRAC motif was altered or 
completed (Fig 5A and B; data not shown).  
Decreased morbidity and mortality in mice infected with recombinant 
viruses expressing M2 CRAC mutants. Some M2 mutations have been shown to have 
no effect in vitro but display decreased in vivo pathogenesis (7, 41, 42). In order to 
65 
 
determine if mutation of the M2 CRAC motif affects in vivo pathogenesis, mice were 
infected with rWSN viruses expressing the wildtype M2, M2 R54F, or M2 delCRAC. 
When intranasally inoculated with 103 TCID50, mice infected with all viruses displayed 
similar survival (Fig 6A). When mice were infected with 105 TCID50 of virus, rWSN 
caused significantly more mortality compared to rWSN M2 R54F and rWSN M2 
delCRAC (Fig 6B). The median time of death for rWSN (7 days) and rWSN M2 R54F 
(11 days) differed as well. Change in body mass induced by infection with 103 TCID50 of 
either rWSN or rWSN M2 R54F was more significant than that induced by rWSN M2 
delCRAC (Fig 6C). Mice infected 105 TCID50 of the viruses did not display significant 
differences in loss of body mass over the first 6 days of infection, despite the decreased 
mortality of mice infected with the CRAC altered recombinant viruses (Fig 6D). 
Infection of mice with 105 TCID50 of rUd M2F54R did not result in a significant increase 
in virus replication or morbidity when compared to rUd, suggesting that restoration of the 
complete CRAC domain did not enhance in vivo replication of rUd (data not shown). 
This data indicates that elimination of the M2 CRAC motif leads to a modest attenuation 
of virus virulence in the mouse model of infection despite no obvious defects in in vitro 
virus replication. 
 Alteration of the M2 CRAC motif does not affect replication of recombinant 
influenza A viruses in mTEC cultures. Given the discrepancy between the ability of the 
recombinant viruses to replicate in tissue culture cells and their attenuation in the mouse 
model of infection, we investigated whether virus infection of mTEC cultures would 
better reflect the in vivo virus phenotypes. These primary cell cultures are differentiated 
into cell types normally found in the mouse trachea and therefore represent a faithful 
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tissue culture surrogate for virus infection of the airways (11, 24, 27). There was no 
statistically significant difference in the replication of the mutant viruses in mTEC 
cultures as compared to the corresponding wildtype virus (Fig 7), suggesting that 
replication in mTEC cultures was not compromised by altering the CRAC motif. 
 
Discussion  
This study sought to investigate the role of the CRAC motif found in the M2 
protein of two influenza A virus strains. The R54F mutation in the WSN M2 protein was 
made to mimic the amino acid found at that residue in Ud M2. The rWSN M2 R54F 
mutant virus still contains a putative consensus CRAC sequence because it has another 
basic amino acid at residue 56. This could explain why this virus has an intermediate 
change in virulence when compared to rWSN and rWSN delCRAC. Mutation of WSN 
M2 to either R54F or delCRAC leads to no changes in virus replication in vitro. 
Likewise, completion of the CRAC motif in the Ud M2 protein also has no effect on 
virus replication in MDCK cells, CaLu-3 cells, or in mTEC cultures. Together, this 
suggests that the CRAC motif is not required for in vitro replication of influenza A virus.  
 Even though the CRAC motif is not essential for in vitro virus replication, 
mutation of the motif resulted in decreased morbidity and mortality when mice were 
infected with a virus lacking the CRAC motif. The decreased pathogenesis of mutants 
may suggest that the CRAC motif of the M2 protein may be a virulence determinant in 
that it is not required for in vitro virus replication but is critical for efficient virus 
infection in animal models. It is also possible that presence of a complete CRAC motif in 
M2 protein contributes to virus infection of other cell types such as alveolar epithelial 
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cells or macrophages. Rossman et al. recently demonstrated that amino acids outside of 
the CRAC domain contribute to the cholesterol binding of M2 and mutation of these 
amino acid sequences leads to decreased in vitro replication (31). The M2 protein only 
showed cholesterol binding activity in the context of a virus infection and changes at 
multiple amino acids that line the hydrophobic face of a membrane proximal alpha helix 
of the protein were demonstrated to be critical for in vitro virus replication. This suggests 
that the CRAC motif in and of itself, is not required for influenza virus replication in 
vitro, a fact supported by our data.  
The cytoplasmic tail of M2 has been implicated in the stabilization of the open 
state of the M2 ion channel (33, 38), virion incorporation of M1 and vRNP (12, 19, 20), 
virus morphology (12), and virus infectivity (2, 12, 19, 20, 36). Although the 
transmembrane domain of M2 has been studied by NMR and crystallography, the 
structure of the cytoplasmic domain is less well understood (33, 35). The structure of 
residues 45-60 of the M2 cytoplasmic tail has been determined by NMR in concert with 
the transmembrane domain (33), but the structure of the entire cytoplasmic tail has yet to 
be determined. Residues 47-50 form a short, flexible loop linking the transmembrane 
domain to a C-terminal amphipathic helix (residues 51-59) that forms a stable “base” 
important for holding the tetramers together during the conformational changes 
associated with ion channel activation. The CRAC domain and a site for palmitoylation 
(Ser 50) fall into these regions and it has been speculated that these modifications may 
stabilize the interaction of the M2 cytoplasmic tail with lipid membranes (33). 
Elimination of the CRAC motif or the M2 palmitoylation site (7) does not alter virus 
replication in vitro, but does yield viruses that are attenuated in the mouse model of 
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infection. This data argues against a critical role for these two sequences in virus 
replication, though both sequences are essential for maintaining virus virulence in vivo. 
While these sequences may be dispensable for virus replication, this does not imply that 
this region of the M2 protein is not important for M2 function either as a structural motif, 
or through properties as yet undefined.  
 The CRAC motif in the M2 protein is not required for incorporation of M2 into 
virions, nor does it affect the incorporation of other viral proteins. Alternate methods 
mediating the incorporation of M2 into virions must therefore exist. One study suggests 
that the ectodomain of M2 can drive a foreign protein to be incorporated into influenza A 
virus particles (26) but there are no known interactions between the M2 ectodomain and 
the ectodomains of the other viral glycoproteins. The mechanism by which a limited 
amount of M2 is incorporated into virus particles despite the high amounts of M2 located 
in the plasma membrane but not in the same membrane microdomains as the 
glycoproteins remains to be determined. 
 
Materials & Methods 
Plasmids. The plasmid pCAGGS (25) was used for M2 expression in mammalian 
cells. A plasmid expressing the M2 cDNA from influenza A/Udorn/72 (Ud M2) has been 
described previously (20). The M2 coding region from influenza A/WSN/33 (Genebank 
Accession number ABF21317) was amplified by RT-PCR and cloned as described 
previously for M2 Ud (18). A WSN M2 cDNA encoding a protein sensitive to the 
antiviral drug amantadine was constructed by changing the amino acid at position 31 
from arginine to serine (N31S) (36). All M2 mutations were introduced into the 
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expression plasmids by overlap extension PCR and the sequences of the mutated 
plasmids were confirmed. Primer sequences are available upon request.  
 The pBABE plasmid, which expresses puromycin N-acetyltransferase, was used 
to generate stable cell lines expressing mutant M2 proteins as previously described (21). 
 In order to generate recombinant influenza viruses expressing M2 proteins with 
altered CRAC motifs, mutations were introduced into the pHH21 M segment plasmids 
via site-directed mutagenesis (Stratagene). The sequence of the entire M segment of the 
resulting plasmid was confirmed. 
Cells. Madin-Darby canine kidney (MDCK) cells, human lung adenocarcinoma 
(CaLu-3) cells (ATCC HTB-55), and human embryonic kidney (293T) cells (36) were 
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS, Atlanta Biologicals), 100U/mL penicillin (Invitrogen), 100μg/mL 
streptomycin (Invitrogen), 1mM sodium pyruvate (Sigma), and 2mM GlutaMAX 
(Invitrogen). Cells were maintained at 37°C in a humidified 5% CO2 environment. 
Generation of stable cell lines. MDCK cells stably expressing M2 proteins were 
generated as described previously (20). Briefly, MDCK cells were cotransfected in 
suspension with 1μg pCAGGS M2 expression plasmid and 0.5μg pBABE puromycin 
expression plasmid using 9μL of Lipofectamine 2000 (Invitrogen) as per the 
manufacturer’s protocol. Cells were plated into 6 well plates, selected using 7.5μg/mL 
puromycin dihydrochloride (Sigma), and single colonies were isolated and expanded. 
Expression of M2 was confirmed by indirect immunofluorescence staining of surface M2 
using monoclonal antibody (MAb) 14C2. M2 expressing cells were maintained with 5μM 
amantadine hydrochloride (Sigma). 
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 Viruses. The viruses used in this study were rWSN and rUd (recombinant 
versions of A/WSN/33 and A/Udorn/72, respectively). Viruses were generated using a 
12-plasmid rescue system described previously (19, 20, 23, 36). The entire coding region 
of the M segment sequence of all rescued viruses was confirmed. There were no 
discernable differences in plaque size or morphology between any of the recombinant 
viruses (data not shown).  
 Virus growth curves were performed at a multiplicity-of-infection (MOI) of 
~0.001. For complementation assays, MDCK cells expressing mutant M2 proteins were 
infected with recombinant viruses that were functionally deleted for the expression of M2 
(M2stop viruses) as described previously (19). For recombinant viruses, mutant M2-
expressing viruses were used to infect MDCK or CaLu-3 cells. Cells were infected by 
twice washing confluent 6 well plates of MDCKs with phosphate buffered saline (PBS, 
Invitrogen) then infecting with the indicated viruses in 500μL infectious media (DMEM 
supplemented with 5% bovine serum albumin (BSA, Calbiochem), 100U/mL penicillin, 
100μg/mL streptomycin, 2mM GlutaMAX, and 4μg/mL N-acetyl trypsin (NAT, Sigma)) 
at room temperature with rocking for 1hr. Cells were then washed twice with PBS and 
incubated with 500μL infectious media. Media was removed and replaced with fresh 
media at the indicated timepoints. Infectious virus titers were quantified by determining 
the 50% tissue culture infectious dose (TCID50) on MDCK cells (for M2-expressing 
viruses) or MDCK cells expressing WSN M2 N31S (for M2Stop viruses). Media lacking 
trypsin was used for infection of CaLu-3 cells. Standard error of the mean is graphed 
from infections done in duplicate or triplicate. The experiments were repeated at least 
twice and one representative example is graphed. 
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 For microscopy, MDCK cells were grown to confluency on tissue culture treated 
glass coverslips and media changed every 2 days. Four days after confluence, cells were 
washed twice with PBS, infected with 500,000 TCID50 (~0.9 MOI) of the indicated virus 
in 500μL medium for 1 hr at room temperature. Cells were then washed, the media was 
replaced and the cells incubated at 37C for 15 hours. 
Virus purification. Virus particles were isolated from the supernatants of MDCK 
cells infected at an MOI of 5 for 15hr. Cell debris was removed by centrifugation at 1,900 
g for 10min at 4°C. Virus particles were then concentrated through a 20% sucrose 
cushion with centrifugation at 118,000 g in a TH641 rotor (Sorval) for 1hr at 4°C. Virus 
pellets were resuspended in 100μL PBS and mixed 1:1 in 2x SDS-PAGE sample buffer. 
SDS-PAGE and Western Blotting. MDCK cells were lysed in 1% SDS (Fisher 
Scientific) in PBS and mixed 1:1 in 2X SDS-PAGE sample buffer. Polypeptides were 
resolved on 17.5% polyacrylamide gel with 4M urea and transferred to polyvinylidene 
difluoride membranes (PVDF, Millipore). Membranes were blocked with PBS containing 
0.3% Tween-20 (Sigma) and 5% dry milk, incubated 1hr RT with primary antibody, 
washed three times with PBS with 0.3% Tween-20, incubated 1hr RT with secondary 
antibody, and washed four times with PBS containing 0.3% Tween-20. The primary 
antibodies used were mouse α-M2 14C2 MAb (1:1,000 dilution) (44), mouse α-M1 HB-
64 MAb (1:100 dilution) (20, 43), mouse α-NP HB-65 MAb (1:100 dilution) (20, 43), 
goat α-A/Udorn/72 serum (1:500 dilution) (45), or goat α-HA0 A/PR/8/34 (1:500 
dilution, V-314-511-157; National Institute of Allergy and Infectious Diseases). 
Secondary antibodies were goat α-mouse immunoglobulin G (IgG) conjugated to 
AlexaFluor 647 (4μg/mL, Invitrogen), donkey α-mouse IgG conjugated to AlexaFluor 
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647 (4μg/mL, Invitrogen), donkey α-goat IgG conjugated to AlexaFluor 647 (4μg/mL, 
Invitrogen). Membranes where then scanned using an FLA-5000 (FujiFilm), samples 
were normalized to total M1 and M2 expression relative to wild type protein was 
determined.  Structural proteins and oligomeric forms of M2 are indicated.  
Flow Cytometry. Cells were removed from the tissue culture plates with trypsin 
treatment. The trypsin was inactivated with serum containing media and cells were 
washed once with PBS and incubated on ice for 30min, in the presence of blocking buffer 
(PBS supplemented with 0.5% BSA and 3% normal goat serum (NGS, Sigma)). Cells 
were then incubated for 1hr on ice with an antibody that recognizes the M2 ectodomain 
(14C2 MAb, 1:1000 dilution), washed three times with PBS, incubated with goat α-
mouse IgG conjugated to AlexaFluor 488 (4μg/mL, Invitrogen) for 1hr on ice, and 
washed three times with PBS. Cells were then fixed with 1% formaldehyde (Fisher 
Scientific) in PBS for 15min at room temperature. The cells were analyzed on a 
FACSCalibur (Beckton Dickinson) and quantified using FlowJo software (Tree Star). All 
antibody dilutions were made in blocking buffer.  
Microscopy. The cells were treated as for flow cytometry except antibodies were 
goat α-H3 sera raised against A/Aichi/2/68 (1:500 dilution, V-314-591-157; National 
Institute of Allergy and Infectious Diseases) and donkey α-goat IgG conjugated to 
AlexaFluor 555 (4μg/mL, Invitrogen). After incubation with antibodies, the cells were 
fixed with 2% paraformaldehyde (Sigma) in PBS for 15min at room temperature, washed 
twice with PBS, then mounted on slides using ProLong Gold anti-fade (Invitrogen). 
Samples were imaged on a Nikon Eclipse 90i microscope. For quantification, 10 or 20 
images of random fields of view were taken with a 20x objective in two separate 
73 
 
experiments. For each image, the number of infected cells and cells with filaments were 
counted and used to determine the percentage of infected cells expressing filaments. Data 
from one representative experiment is shown. For high magnification images, Z-sections 
were taken at 0.3μm intervals on a Leica 510 Meta LSM confocal microscope using a 
100x oil-immersion lens. Volocity 3D imaging software (Improvision) was used to 
analyze and flatten Z-sections. 
Transmission Electron Microscopy. MDCK cells were grown to confluency in 
3.5cm dishes and infected at an MOI of ~5 with either rUd or rUd M2 F54R. At 10hpi, 
cells were washed twice with PBS and fixed with 2mL of fresh fixative (2% 
glutaraldehyde, 0.1M cacodylate, 3% sucrose, and 3mM CaCl2 in PBS pH7.4) overnight 
at 4°C. Cells were post-fixed with 1% osmium tetroxide reduced in potassium 
ferrocyanide for 1 hr at 4°C. After fixation, cells were stained en bloc with a 2% aqueous 
solution of uranyl acetate and dehydrated in graded ethanol. Embedding was done in 
Eponate 12 Resin (Ted Pella). Thin sections (70-90nm) were cut on a Reichert-Jung 
Ultracut E and placed on 200 mesh copper grids. The sections were stained with uranyl 
acetate and lead citrate and viewed on a Hitachi 7600 TEM with an AMT digital camera. 
Infection of BALB/c mice. Six to 8-week old female BALB/c mice (Charles 
River) were used as described previously (24, 42). Mice were anesthetized and 
administered an intranasal inoculation of 103 or 105 TCID50 of rWSN, rWSN M2 R54F, 
or rWSN M2 delCRAC virus diluted in 20μL DMEM supplemented with 100U/mL 
penicillin, 100μg/mL streptomycin, and 4μg/mL NAT. Animals were monitored for 14 
dpi for morbidity and mortality (42). Changes in body mass are graphed as percent of 
starting mass. 
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Infection of mTEC cultures. Mouse tracheal epithelial cells (mTECs) were 
harvested, isolated, and differentiated as described previously (10, 24). Cultures were 
infected via the apical chamber with 3,300 TCID50 in 100μL of media, ~0.01 MOI 
assuming all cells are susceptible to infection. After 1hr, apical supernatants were 
removed and replaced with fresh media. At the indicated hpi, apical and basolateral 
supernatants were removed and replaced with fresh media. Throughout the infection, 
infectious media without NAT was used. Infectious virus titers were quantified at 
indicated times as above. Standard error of the mean is graphed from infections done in 
duplicate. 
Statistical Analysis. Infectious virus production and body mass changes were 
analyzed using mixed ANOVAs with time and virus as the independent variables. Protein 
concentrations and differences in the percentage of cells with filaments were calculated 
using t-tests. Mean day of death was determined by logrank test. Significant interactions 
were further evaluated using the Tukey method for pairwise multiple comparisons. 
Statistically significant differences of p<0.05 (*) or p<0.01 (**) are indicated and all 
analyses were done with Prism 4.0 (GraphPad Software Inc.).  
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Figure Legends 
 
Figure 1. Sequence alignment of M2 residues 46-56. The amino acids that define the 
CRAC motif are in bold and substitutions that disrupt or complete the consensus are 
indicated. An asterisk indicates no change in sequence. The rWSN M2 R54F mutant still 
contains a potential CRAC consensus sequence due to the presence of another basic 
amino acid at position 56. 
 
Figure 2. Expression and function of M2 proteins with modified CRAC motifs. (A 
and D) MDCK cells expressing the indicated M2 proteins were analyzed by Western 
blotting to detect disulfide linked oligomeric forms of the M2 protein. Monomers, dimers 
and trimers are indicated and some higher order oligomers can be detected. (B and E) The 
number of cells expressing M2 at the cell surface was quantified by flow cytometry from 
the indicated stably transfected MDCK cell lines. (C and F) The ability of the indicated 
stably transfected MDCK cells to complement infection with a recombinant influenza 
virus that does not encode the full length M2 protein was assessed by infecting the cells 
with the indicated recombinant virus and quantifying infectious virus production at 
various hours post infection (hpi). The average and standard error of the mean are 
graphed. The standard error is smaller than the size of the individual points. The limit of 
detection is marked by a dotted line. Proteins or recombinant viruses based on the rWSN 
(A-C) and rUd virus strains (D-F) were used. 
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Figure 3. The effects of altering the CRAC motif on replication in tissue culture. (A 
and D) MDCK cells were infected with the indicated viruses at an MOI of ~3 and the cell 
surface expression of M2 protein was measured by flow cytometry at 15 hours post 
infection (hpi). The relative expression of M2 represents the mean channel fluorescence 
of the indicated infected cells divided by the mean channel fluorescence of the wildtype 
infected cells. MDCK (B and E) or CaLu-3 (C and F) cells were infected at an MOI of 
~0.001 with the indicated recombinant viruses. At the indicated hpi, infected cell 
supernatants were harvested and the number of infectious virus particles determined by 
TCID50 assay. Data points represent the average and standard error of the mean. The 
horizontal dotted line is the limit of detection. 
 
Figure 4. The effects of completing the CRAC motif on formation of filamentous 
virus particles. MDCK cells were infected with 500,000 TCID50 (~0.9 MOI). At 15hpi, 
immunofluorescence staining was performed for HA and visualized by confocal 
microscopy. Confocal Z-sections (taken with a 100x objective) of rUd (A) or rUd M2 
F54R (B) infected cells were flattened and show viral filaments for both viruses. The 
percentage of infected cells showing filaments was determined from 10-20 images taken 
with a 20x objective on an epifluorescence microscope (C). One representative 
experiment is shown. For TEM, MDCK cells were infected at an MOI of ~5. Samples 
were processed for transmission electron microscopy at 10 hpi. Cells were infected with 
rUd (D) or rUd M2 F54R (E). Arrows indicate microvilli, solid arrowheads indicate 
filamentous virus particles, and empty arrowheads mark either spherical virus particles or 
cross-sections of filamentous virus particles. 
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Figure 5. The effects of altering the CRAC motif on incorporation of structural 
proteins. MDCK cells were infected with the indicated viruses at an MOI of 5. At 15hpi, 
virus particles were collected and concentrated through a 20% sucrose cushion at 118,000 
g for 1hr. Virus pellets were resuspended and incorporation of viral proteins was 
determined by Western blot with antibodies which detect the structural proteins HA, NP, 
M1, and M2. (A and B) Representative Western blots showing incorporation of viral 
proteins into virions. (C and D) Quantification of full length M2 and total M2 from 
Western blot analysis of replicate virion incorporation assays. Increased contrast was 
used on the Western blot of virion-associated proteins to allow for detection of low 
intensity bands. Relative expression was determined by the negative log of M1 
normalized data. Recombinant viruses based on the rWSN (A and C) or rUd virus strains 
(B and D) were used. * = p<0.05. 
 
Figure 6. Mortality and morbidity of mice infected with recombinant influenza 
A/WSN/33 viruses encoding M2 proteins with altered CRAC motifs. Mice were 
administered an intranasal dose of 103 (A and C) or 105 (B and D) TCID50 of the 
indicated viruses and monitored for 14 days post infection (dpi). (A and B) Mortality and 
(C and D) morbidity associated with infection, as judged by loss of starting weight. Data 
points indicate the average and standard deviation. Significant differences in (B) are 
between the CRAC altered viruses and rWSN while in (C) the differences are between 
rWSN M2 delCRAC and the other two viruses. * = p<0.05 and ** = P<0.01. 
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Figure 7. The effects of altering the CRAC motif on replication in mouse tracheal 
epithelial cell (mTEC) cultures. mTEC cultures were infected with 3300 TCID50 (~0.01 
MOI) of the indicated recombinant viruses in the rWSN (A) or rUdorn (B) genetic 
backgrounds. At the indicated hpi, infected cell supernatants were harvested and the 
number of infectious virus particles determined by TCID50 assay in MDCK cells. Data 
points represent the average and standard error of the mean. The horizontal dotted line is 
the limit of detection. 
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Figure 1. Sequence alignment of M2 residues 46-56.  
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Figure 2. Expression and function of M2 proteins with modified CRAC motifs. 
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Figure 3. The effects of altering the CRAC motif on replication in tissue culture. 
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Figure 4. The effects of completing the CRAC motif on formation of filamentous 
virus particles. 
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Figure 5. The effects of altering the CRAC motif on incorporation of structural 
proteins.  
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Figure 6. Mortality and morbidity of mice infected with recombinant influenza 
A/WSN/33 viruses encoding M2 proteins with altered CRAC motifs. 
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Figure 7. The effects of altering the CRAC motif on replication in mouse tracheal 
epithelial cell (mTEC) cultures.   
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CHAPTER 3 
 
Mutations in the membrane proximal region of the influenza A virus M2 protein 
cytoplasmic tail have modest effects on virus replication 
 
 
This chapter is reprinted here essentially as published. 
 
Shaun M. Stewart and Andrew Pekosz. 
J Virol doi:10.1128/JVI.05970-11 (2011). 
  
95 
 
Abstract 
 Influenza A virus encodes M2, a proton channel that has been shown to be 
important during virus entry and assembly. In order to systematically investigate the role 
of the membrane proximal residues in the M2 cytoplasmic tail on virus replication, we 
utilized scanning and directed alanine mutagenesis in combination with trans-
complementation assays and recombinant viruses. The membrane proximal residues 46-
69 tolerated numerous mutations with little, if any, affect on virus replication suggesting 
that protein structure, rather than individual amino acid identity in this region, may be 
critical for M2 protein function. 
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Introduction 
 Influenza A virus is a member of the Orthomyxovirdae family whose genome 
consists of 8 negative-sense RNA segments which encode 10 or 11 proteins. The highly 
conserved integral membrane protein M2 is encoded by segment 7 via a spliced mRNA, 
consists of 97 amino acids, and forms disulfide-linked tetramers which have a pH-gated, 
proton-selective ion channel activity. M2 is a type III integral membrane protein with an 
extracellular amino-terminus and intracellular carboxy-terminus. M2 is required during 
virus entry, where it translocates protons into the virion interior which allows for the 
dissociation of viral ribonucleoprotein complexes (vRNPs) from the site of virus-cell 
membrane fusion, thereby allowing vRNP transport to the nucleus (12, 18, 26). M2 is 
also required during virus assembly where its cytoplasmic tail is required for proper 
incorporation of vRNPs into budding virions (9, 19, 20). The M2 protein and a peptide 
corresponding to an amphipathic helix in the membrane proximal cytoplasmic tail of the 
protein, have been shown to induce membrane curvature and scission in unilamellar 
vesicles and were suggested to be necessary for membrane scission and virion release 
(31). However, virus-like particles (VLPs) (3, 4, 8, 15, 17, 39) and virions (6, 9, 13) can 
be released in the absence of M2. 
Various deletions and mutations in the M2 protein, and in particular the 
cytoplasmic tail, attenuate influenza A virus replication significantly (9, 14, 19, 20) and 
can be complemented with full length M2 expressed in trans (3, 9, 19, 20, 35). Residues 
within the cytoplasmic tail form a canonical cholesterol-binding motif (CRAC) and have 
been shown to mediate cholesterol binding in purified bacterially expressed protein and 
during virus infection but not when expressed alone in mammalian cells (30, 33, 37). 
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Mutation of residues within the CRAC motif caused no defect in virus replication in 
tissue culture but a slight attenuation of virus in vivo (35). Although structural studies 
have not been performed on the full-length M2 sequence, NMR studies on peptides 
corresponding to the transmembrane domain and portions of the cytoplasmic tail reveal 
that residues adjacent to the transmembrane domain form an amphipathic helix (25, 32, 
34).  
 To systematically investigate the role of the membrane proximal residues (amino 
acids 46-69) in the M2 cytoplasmic tail on virus replication, we substituted alanine 
residues at a number of positions and assessed M2 protein function with a trans-
complementation assay and reverse genetics. We show that the residues 46-69 tolerate 
numerous mutations with little, if any, attenuation of virus replication in both 
complementation assays and growth curves of recombinant viruses. Therefore, despite 
being highly conserved and forming a stable structure, this region can tolerate a high 
number of amino acid substitutions without significantly affecting influenza A virus 
replication. 
 
Materials and Methods 
Plasmids. The plasmid pCAGGS (24) M2Ud expressing the M2 cDNA from 
influenza A/Udorn/72 has been described previously (20). All M2 mutations were 
introduced into the expression plasmid by overlap extension PCR (35). The pHH21 M 
segment plasmid, which encodes the entire M segment used for generating recombinant 
viruses (20), was mutated via QuikChange Site-Directed Mutagenesis (Stratagene) (35). 
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All inserts in mutant plasmids were confirmed by sequencing. Primer sequences are 
available upon request. 
Cells.  Madin-Darby canine kidney (MDCK) cells were cultured in Dulbecco’s 
modified Eagle medium (DMEM, Sigma) supplemented with 10% fetal bovine serum 
(FBS, Atlanta Biologicals), 100U/mL penicillin (Invitrogen), 100µg/mL streptomycin 
(Invitrogen), 1mM sodium pyruvate (Sigma), and 2mM GlutaMAX (Invitrogen). Cells 
were maintained at 37°C in a humidified 5% CO2 environment. 
MDCK cells stably expressing wildtype M2Ud or M2WSN N31S have been 
described previously (9, 35). The N31S mutation conveys amantadine sensitivity to the 
M2 protein encoded by influenza A/WSN/33 (11, 36). The pBABE plasmid, which 
expresses puromycin N-acetyltransferase (21) was used to generate MDCK cells stably 
expressing mutant M2 proteins as described previously (35). Cells expressing M2 
proteins were maintained with 5µM amantadine hydrochloride (Sigma) and 7.5µg/mL 
puromycin dihydrochloride (Sigma). 
Viruses. The wildtype viruses used in this study, rUd and rWSN (recombinant 
versions of A/Udorn/72 [H3N2] and A/WSN/33 [H1N1]), as well as viruses encoding 
functional deletions of the M2 open reading frame, have been described (20, 22, 36). 
Recombinant viruses were generated using a 12-plasmid rescue system described 
previously (19, 20, 22, 36). Recombinant viruses expressing mutant M2 proteins were 
generated as described (9), by replacing the pHH21 M segment plasmid with one 
encoding the indicated mutant M2 open reading frame. Viruses expressing mutant M2 
proteins were plaque purified and grown in MDCK cells stably expressing M2WSN 
N31S in order to alleviate any selective pressure on the virus to revert the M2 mutations. 
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The entire coding region of the M segment of all rescued viruses was confirmed by 
sequencing. 
Virus infections. Multi-step virus growth curves were performed at a multiplicity 
of infection (MOI) of 0.001 50% tissue culture infectious doses (TCID50) per cell. For 
complementation assays, MDCK cells expressing mutant M2 proteins were infected with 
recombinant viruses that do not encode the full-length M2 protein (M2Stop viruses) as 
described (19). For recombinant viruses, mutant M2-expressing viruses were used to 
infect MDCK cells. Cells were infected by twice washing confluent 12-well plates with 
phosphate-buffered saline with calcium and magnesium (PBS+, Invitrogen) then 
infecting with the indicated viruses in 250µL infectious media (DMEM supplemented 
with 0.5% bovine serum albumin (BSA, Sigma), 100U/mL penicillin, 100µg/mL 
streptomycin, 1mM sodium pyruvate, 2mM GlutaMAX, and 4µg/mL N-acetyl trypsin 
(NAT, Sigma)) at room temperature with rocking for 1hr. Cells were then washed twice 
with PBS+ and incubated with 500µL infectious media at 37°C. At indicated times, 
media was removed, stored at -80°C, and replaced with fresh media. Infectious virus 
titers were determined by TCID50 assay on MDCK cells expressing M2WSN N31S. 
 High MOI infections (MOI 0.5 or MOI 5) were performed using the protocol for 
multi-step growth curves with the exception that both NAT and BSA were omitted during 
all steps of infection. For protein expression studies, the media was removed at 16hpi and 
cells were processed for Western blot analysis. For virion composition, the cell lysates 
and supernatants were collected at 12hpi. Cell debris was removed from supernatants by 
centrifugation at 1300g for 10 min at 4 °C. Virus particles were then concentrated 
through a 35% sucrose cushion with centrifugation at 182,000g in a Sorvall TH-641 rotor 
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for 1 h at 4 °C. Virus pellets were resuspended in 200 μL PBS, mixed 3:1 in 4xSDS–
PAGE sample buffer, and analyzed along with the cell lysates by Western blot analysis. 
Plaque assay.  Plaque assays were carried out by infecting confluent 6-well plates 
of MDCK cells with indicated viruses serially diluted in infectious media. Cells were 
washed twice with PBS+, infected with 250µL of virus dilutions for 1hr at room 
temperature with rocking, the inoculums were aspirated, and cells were overlaid with 
DMEM (Invitrogen) containing 1% agarose (Invitrogen), 0.5% BSA, 100U/mL 
penicilillin, 100µg/mL streptomycin, 2mM GlutaMAX, and 4µg/mL NAT. After 
overlays had solidified, the cells were incubated at 37°C for 3 days. Cells were then fixed 
with 4% formaldehyde (Fisher Scientific) in PBS for 1hr at room temperature and stained 
with a Naphthol Blue Black solution overnight. Individual plaque diameters were 
measured from scanned images using ImageJ (NIH).  
Microscopy.  MDCK cells were grown to confluency on tissue culture treated 
glass coverslips (Fisher Scientific) in 12-well plates and media was changed every 2 
days. Four days after confluence, cells were infected with 500,000 TCID50 per well (MOI 
~0.9) in 500µL of infectious media as per high MOI infections above and incubated at 
37°C. At 15hpi, the cells were incubated on ice for 15min, washed twice with cold PBS+, 
and blocked for 30min on ice in PBS with 0.5% BSA and 3% normal goat serum 
(Sigma). Surface staining was performed for 1hr on ice in blocking solution containing 
goat anti-H3 sera raised against A/Aichi/2/68 (1:500 dilution, V-314-591-157; National 
Institute of Allergy and Infectious Diseases). Cells were then washed 3 times with cold 
PBS+, fixed for 10min with 2% paraformaldehyde (Sigma) in PBS at room temperature 
(RT), and incubated 1hr at RT with blocking solution containing donkey anti-goat IgG 
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conjugated to AlexaFluor 555 (4µg/mL, Invitrogen). Cells were then washed twice with 
PBS+ and mounted on slides using ProLong Gold anti-fade (Invitrogen). 
 Samples were imaged on a Nikon Eclipse 90i epifluorescence microscope. 
Twenty non-overlapping images were taken of each sample using a 20x objective. For 
each image, the total number of infected cells and cells expressing filaments were 
counted and used to determine the percentage of infected cells expressing filaments. 
TCID50 assay. MDCK cells expressing M2WSN N31S were plated in 96-well 
plates. When confluent, cells were washed twice with PBS+, infected with 100µL of 
virus serially diluted in infectious media, and incubated for 4 days at 37°C. Cells were 
then fixed by adding 50µL of 4% formaldehyde in PBS, stained with a Naphthol Blue 
Black solution, and scored for cytopathic effect. The 50% tissue culture infectious dose 
(TCID50) was calculated by the method of Reed and Muench (27). 
SDS-PAGE and Western blotting.  Cells were lysed in 1% SDS (Fisher 
Scientific) in PBS and mixed 1:1 in 2x SDS-PAGE sample buffer. Purified virus particles 
were mixed 3:1 with 4x SDS-PAGE sample buffer. Sample buffer for samples analyzed 
for total expression contained the reducing agent DTT while samples analyzed for 
oligomerization did not. Proteins were resolved on 17.5% polyacrylamide gel with 4M 
urea and transferred to polyvinylidene difluoride membranes (PVDF-FL, Millipore). 
Wash buffer contained PBS with 0.3% Tween-20 (Sigma) and block buffer was wash 
buffer with 5% dry milk added. Membranes were blocked for 30min at RT, incubated 2hr 
RT with primary antibody, washed three times each for 5min, incubated 1hr RT with 
secondary antibody, and washed four times each for 5min. Primary and secondary 
antibodies were diluted in block buffer. The primary antibodies used were a mouse anti-
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M2 14C2 MAb (1:500 dilution) (40), goat anti-A/Udorn/72 (1:500 dilution) (41), and a 
mouse anti-β-actin AC-15 MAb (1:10,000 dilution, Abcam). The AlexaFluor 647 
conjugated secondary antibodies used were a goat anti-mouse immunoglobulin G (IgG), a 
donkey anti-goat IgG, and a donkey anti-mouse IgG (all 1:500 dilution, Invitrogen). For 
visualization, membranes were scanned using an FLA-5000 phosphorimager (FujiFilm). 
Sequence alignments. All M2 protein sequences from H1N1 and H3N2 influenza 
A virus strains (excluding pandemic 2009 H1N1 and laboratory strains) were obtained 
from the NCBI Influenza Virus Sequence Database (1). Sequences were aligned using 
ClustalW 2.0.10 (16). The percent of the sequences which encode the most conserved 
residue at each amino acid was determined using WebLogo 3 (7). 
Statistical analysis.  Plaque diameters and percentage of infected cells 
expressing filaments were compared using student t-tests. Growth curves were analyzed 
using mixed ANOVAs and Bonferroni post-tests with time and virus titer as independent 
variables in trans-complementation assays or in growth assays of recombinant viruses. 
2Statistically significant differences of *p<0.05, **p<0.01, and ***p<0.001, are 
indicated. All analyses were done with Prism 4.0 (GraphPad Software Inc.). 
 
Results 
Oligomerization and expression of mutant M2 proteins in stable cell lines. 
The membrane proximal region of the M2 protein cytoplasmic tail consists of a region 
that displays some sequence variability (amino acids 47-57) and a region that shows very 
high conservation (amino acids 58-69) among seasonal influenza A virus strains (Fig 
1A). In order to determine if residues 46-69 of the M2 protein cytoplasmic tail are 
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required for protein function, two types of alanine-substitution mutations were generated 
(Fig 1B). First, triple-scanning alanine mutations were generated across the region. 
Second, an NMR structure (34) of the M2 protein was utilized to select amino acids 
corresponding to two separate faces (M2UdCYTO and M2UdPORE) of the amphipathic 
helix within the membrane proximal region cytoplasmic tail. Figure 1C shows the 
residues 52, 53, 56, 57 and 60 of the helices which face the cytoplasm and were mutated 
to alanines in the M2UdAlaCYTO mutant. Figure 1D shows the residues 51, 54, and 55 
of the helix which face inward toward the amphipathic helixes of the other M2 peptides 
and were mutated to alanines in the M2UdAlaPORE mutant. Alanine substitutions were 
utilized in order to minimize structural perturbations on the amphipathic alpha helix 
while still assessing the role of amino acid side chains on interactions with viral or 
cellular factors.  
 Stably transfected MDCK cells were generated which express the mutant M2 
proteins. All cell lines expressed M2 above the level required to complement M2-
deficient viruses (Fig 2A) (20). Additionally, the mutations do not alter the 
oligomerization potential of M2 as determined by SDS-PAGE and Western blot analysis 
under non-reducing conditions (Fig 2B). 
M2 proteins are able to complement M2-null viruses. To study mutations 
which may be deleterious to M2 function, a complementation assay was utilized (20). 
Stably transfected MDCK cells were infected with two strains of M2-null virus, rUd 
M2Stop (Fig 3A and B) or rWSN M2Stop (Fig 3C and D) (19). Neither rUd M2Stop nor 
rWSN M2Stop are able to produce infectious virus on MDCK cells that do not express 
M2 (Fig 3). The replication of rUd M2Stop in all mutant M2-expressing cell lines was 
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not different from what was observed in wildtype M2-expressing cells (Fig 3A and B), 
indicating that all of the mutated M2 proteins were capable of supporting rUdorn virus 
replication.  
rWSN M2Stop showed a minor, but statistically significant increase in virus 
replication on cell lines expressing M2UdAla49-51 and M2UdAla67-69, while slightly 
reduced replication was observed on cell lines expressing M2UdAla46-48 and 
M2UdAlaPore (Fig 3 C and D). However, no differences at 24hpi or 48hpi were greater 
than 1 log compared to the titer of rWSN M2Stop on cells expressing wildtype M2 
protein. Despite these minor differences in replication, all cell lines expressing mutant 
M2 proteins supported high levels of replication of rWSN M2Stop, consistent with the 
data utilizing the rUd M2Stop virus (Fig 3A and B). Taken together, this suggests that the 
region of M2 from residues 46-69 is highly amenable to mutation despite being highly 
conserved. 
Replication of recombinant influenza A viruses expressing M2 alanine 
mutations. In order to further investigate the importance of M2 residues 46-69 on virus 
replication, several recombinant viruses were generated in both the rUd and rWSN 
background. Because expression of M2UdAla49-51 supported slightly greater replication 
of rWSN M2Stop at two timepoints, a recombinant virus expressing this mutant were 
generated. A virus expressing M2Ala67-69 were generated because its expression 
supported higher levels of rWSN M2Stop at 48hpi (p<0.001). Lastly, because M2 has 
been shown to interact with M1 (3, 19) and the cytosolically exposed face of the M2 
amphipathic helix could mediate interactions with M1 or other proteins, viruses were also 
generated which express M2AlaCYTO. 
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 Plaque assays were performed on MDCK cells to determine the plaque diameters 
of each recombinant virus. Recombinant viruses expressing M2Ala49-51 or M2Ala67-69 
formed smaller plaques in the rUd background but larger plaques in the rWSN 
background compared to the respective wildtype viruses (Fig 4A and C). Expression of 
M2AlaCYTO resulted in smaller plaques in rWSN but no difference in plaque diameter 
in rUd as compared to wildtype viruses. 
 The decreased plaque diameter in mutant M2-expressing rUd viruses correlated 
with the production of infectious virus at 24hpi in a low MOI growth curve (Fig 4B) but 
by 48hpi there were no differences in infectious virus production between any of the 
viruses. The ability of mutant M2-expressing rWSN viruses to form large or small 
plaques did not fully correlate with their ability to replicate in a low MOI growth curve 
(Fig 4D). rWSN expressing M2Ala49-51 formed larger plaques and had higher infectious 
virus titers at 24hpi in the multi-step growth curve as compared to wildtype virus. 
However, rWSN expressing M2Ala67-69 formed slightly larger plaques compared to 
wildtype virus but resulted in similar levels of infectious virus at both 24hpi and 48hpi. 
Additionally, expression of M2AlaCYTO in rWSN resulted in smaller plaques but more 
infectious virus at 24hpi. Interestingly, despite some statistically significant changes at 
24hpi, all mutant M2-expressing rUd and rWSN viruses formed similar amounts of 
infectious virus at 48hpi compared to their respective wildtype recombinant viruses 
suggesting that the membrane proximal region 46-69 of M2 can tolerate significant 
mutations without eliminating the ability of influenza A virus to replicate. 
Expression of M2UdAla67-69 is able to complement a recombinant virus 
expressing M2Ala67-69. Because rUd M2Ala67-69 produced less infectious virus 
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particles at 24hpi but rUd M2Stop replicated to similar levels on cells expressing 
M2UdAla67-69, the growth of rUd M2Ala67-69 was compared to wildtype rUd in 
MDCK, M2Ud-expressing, and M2UdAla67-69-expressing cells (Fig 5). In MDCK cells, 
rUd M2Ala67-69 replicate to lower titers at 12hpi and 24hpi but had formed similar 
amounts of infectious virus at 48hpi (Fig 5A). In M2Ud- or M2UdAla67-69-expressing 
cells, both viruses produced similar amounts of infectious virus particles at all times 
measured (Fig 5B). This indicates that expression of wildtype or or M2UdAla67-69 M2 
is able to rescue any potential defect in production of infectious virus at early times post 
infection. In order to determine if the level of M2 expressed by rUd M2Ala67-69 is 
equivalent to that of wt virus, high MOI infections were performed on MDCK cells. 
Expression of M2 was similar in cells infected by both viruses (Fig 5D), indicating that 
the small defect in the growth of rUd M2Ala67-69 at 12hpi and 24hpi is not due to 
decreased expression of M2 and suggests that perhaps a greater amount of M2 (either wt 
or mutated protein) is needed for this virus to replicate efficiently. 
M2 protein with alanine mutations at F47, F48, I51, Y52, and F55 is partially 
able to complement M2-deficient viruses. Rossman et al. determined that alanine 
substitution of residues F47, F48, I51, Y52, and F55 in the rUd M2 protein (M2AlaHelix, 
Fig 1B & E) resulted in a recombinant virus severely debilitated in growth (30). Given 
the limited effect of the mutations we introduced into the M2 protein on virus replication, 
we sought to compare this mutant to our M2 mutants. Stably transfected MDCK cells 
were generated which express the M2UdAlaHelix protein. The MDCK cell line 
expressing M2UdAlaHelix expressed a similar level of M2 as compared to a cell line 
expressing wildtype M2Ud (Fig 6A). Additionally, the M2UdAlaHelix mutant formed 
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oligomers as determined by SDS-PAGE and Western blot analysis under non-reducing 
conditions (Fig 6B). 
 In order to determine if constitutive expression of M2UdAlaHelix was able to 
complement M2-null viruses, MDCK or M2-expressing MDCK cells were infected at a 
low MOI and the amounts of infectious virus was determined at the indicated time post 
infection. There was a reduction in the ability of M2UdAlaHelix to complement either 
rUd M2Stop (Fig 6C) or rWSN M2Stop (Fig 6D). Both M2-null viruses grew to 
infectious virus titers approximately 1-2 logs lower on M2UdAlaHelix expressing cells 
than wild type M2-expressing cells at both 24hpi and 48hpi, which was a greater 
attenuation than that seen on any other M2-expressing cell lines analyzed. 
Recombinant influenza A virus expressing the M2UdAlaHelix protein is 
attenuated at early time points but grows to similar peak titers. Because the 
attenuation of rUd M2Stop on cells expressing M2UdAlaHelix was less than what was 
expected based on data with a recombinant virus expressing this mutant M2 protein (30), 
we generated a recombinant Ud virus expressing the M2UdAlaHelix protein to further 
characterize this mutation. Plaque assays of this recombinant, rUd M2AlaHelix, on 
MDCK cells showed significantly smaller plaques when compared to wildtype rUd (Fig 
7A). Low MOI growth curves revealed a decrease in production of infectious virus 
particles at 24hpi, but by 48hpi, rUd M2AlaHelix had produced as much infectious virus 
as recombinant wildtype rUd. Sequence analysis of the rUd M2AlaHelix virus produced 
at this timepoint demonstrated that no changes in the M-segment sequence had 
accumulated, indicating that a revertant virus had not emerged (data not shown). The 
ability of rUd M2AlaHelix to form filaments in virus-infected cells was not significantly 
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different when compared to rUd (Fig 7C). The expression levels of HA, NP, and M1 
proteins were similar in cells infected with either wildtype rUd or rUd M2AlaHelix (Fig 
7D). Western blot analysis of pelleted rUd M2AlaHelix virus particles showed no major 
defective in the secretion of virus particles as well as no defect in the incorporation of 
HA, NP, or M1 (Fig 7D). The modest level of attenuation and lack of significant changes 
in structural protein packaging seen with rUd M2AlaHelix was not consistent with what 
was observed in previous reports (30). However, this data is consistent with the data on 
other M2 mutations generated in this region of the protein (Figures 3 and 4), which 
indicate a limited role for membrane proximal amino acids 46-69 of M2 in supporting 
influenza A virus infectious virus production. 
 
Discussion 
 The influenza A virus M2 protein plays a crucial role during several steps of the 
viral life cycle. During virus entry, the ion channel activity of M2 mediates the release of 
vRNPs into the cytoplasm after HA-induced fusion of the viral and cellular membranes. 
Additionally, the M2 cytoplasmic tail is critical for proper incorporation of vRNPs into 
budding particles. The exact mechanism of the incorporation might occur through 
binding of NP and/or M1. Indeed there is support for the latter in that M1 and M2 have 
been shown to interact with each other (3, 19). Two separate M1 binding sites have been 
identified within M2, one within the amino acids 70-77 (3, 19) and another within 
residues 45-69 (19).  
The membrane proximal region consisting of amino acids 46-69 is believed to 
mediate association of M2 with sites of virus budding. This region consists of a 
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palmitoylation site, a cholesterol binding motif, and an amphipathic helix that can insert 
into the lipid bilayer (23, 25, 32, 34, 38). Although palmitoylation was expendable for 
growth in vitro, mutation of the palmitoylated cysteine at residue 50 led to a reduction in 
pathogenesis in mice (10) and was required for the partial raft partitioning of full-length 
M2 in giant plasma membrane vesicles (37). Mutation of the critical residues within the 
cholesterol binding motif caused no effect on in vitro growth but a small reduction of 
morbidity and mortality associated with infection in mice (35). This study sought to 
investigate which residues in the membrane proximal region 46-69 of the M2 protein 
cytoplasmic tail were required for the function of M2 during virus replication. 
 Two distinct recombinant strains of influenza A virus, A/Udorn/72 and 
A/WSN/33, were utilized. rUd is an H3N2 strain that forms both spherical and 
filamentous virus particles while rWSN is an H1N1 mouse-adapted strain that almost 
exclusively forms spherical virus particles (2, 28, 29). While some M2 mutations have 
been shown to be deleterious to virus replication in both virus strains, others have been 
shown to more deleterious in rUd (9, 19). During infection with rUd, less M2 protein is 
expressed in cells and, therefore, less M2 protein is incorporated into virus particles 
compared to infection with rWSN (10, 35).  
 Triple-scanning alanines were made across the residues 46-69 to systematically 
test the necessity of these highly conserved residues for the formation of infectious virus 
particles. Furthermore, two separate faces of the amphipathic helix found in the M2 
protein cytoplasmic tail were also separately mutated to alanines, M2UdAlaCYTO and 
M2UdAlaPORE. All of these M2 mutants were able to complement two strains of 
influenza A viruses lacking functional M2, rUd M2Stop and rWSN M2Stop (Fig 3). 
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Moreover, recombinant viruses expressing several of these M2 mutants were generated 
and grew to similar peak titers at 48hpi (Fig 4). Taken together, these data show that the 
membrane proximal residues 46-69 of the M2 protein can tolerate significant mutations 
without eliminating the ability of virus to replicate. While none of these mutated M2 
proteins had any major effect on the replication of rUdorn viruses, it is interesting to note 
that two mutations, Ala49-51 and Ala67-69, caused a slight but significant increase in 
replication in rWSN. This demonstrates the importance of assessing M2 mutations in 
different influenza A virus strains. The variable results of these mutations may map to 
other viral proteins, as was demonstrated for virus budding (5) and for infectious virus 
production (9, 19). 
 Analysis of a recent NMR structure revealed that some of the nonpolar residues 
within the amphipathic helix from one monomer interact with residues in the loop 
between the transmembrane domain and the amphipathic helix of another monomer (34). 
L46 was shown to interact with F54 and F48 was shown to interact with both F55 and 
L59. . Interestingly, one of the large hydrophobic residues in each of those pairs is 
mutated in the M2AlaPORE mutant, F54 and F55. Despite disruption of these 
interactions, these mutations did not abrogate the functions of the M2 protein during virus 
replication (Fig 3B and D). However, it is conceivable that mutating these residues from 
phenylalanines to alanines was insufficient to fully disrupt these hydrophobic 
interactions. Additionally, the NMR structure revealed that the charged residues K49, 
R53, H57, K60, and R61 project outward and could interact with the negatively charged 
phospholipids. . The M2AlaCYTO mutant has several of these amino acids altered from 
charged residues to alanines (R53A, H57A, and K60A), yet this mutant retains its ability 
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to complement M2-null viruses (Fig 3B and D) and recombinant viruses expressing it 
show no defect in replication (Fig 4B and D). 
 These data contrast somewhat with a study by Rossman et al., that demonstrated a 
critical role for the membrane proximal, cytoplasmic region of the M2 protein in virus 
budding and membrane scission (30). In that study, while single point mutations at 
positions 47, 48, 51, 52 and 55 did not affect virus assembly and budding, combining all 
those mutations led to a greater than 5 log reduction in infectious virus production and a 
decrease in NP incorporated relative to the other viral proteins (30). These mutations 
abrogated the ability of a peptide corresponding to this region of the M2 protein to induce 
membrane scission in unilamellar vesicles and also reduced the ability of full length M2 
to induce VLPs (31). The significance of this is not completely clear since VLPs are 
formed in the absence of M2 expression (3, 4, 8, 15, 17, 39) and viruses encoding either a 
mutation in the M2 5’ splice site or a nonfunctional M2 both express undetectable levels 
of M2 protein yet produce virus particles with decreased infectivity (6, 9, 13), thus 
demonstrating that M2 is not absolutely necessary for membrane scission of influenza A 
virus particles. We also generated an M2 protein with alanine substitutions at positions 
47, 48, 51, 52, and 55 and demonstrated a 1-2 log decrease in infectious virus production 
from cells expressing M2UdAlaHelix compared to cells expressing wildtype M2 in a 
trans-complementation assay. The defect in infectious virus production was more 
pronounced in infections with rUd M2Stop as compared to rWSN M2Stop. A 
recombinant rUd virus encoding the M2AlaHelix was able to form filaments and had no 
defect in NP incorporation (Fig 7C and D) whereas the same virus reported by Rossman 
et al was unable to form filaments and had a defect in NP incorporation (30). The rUd 
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M2AlaHelix that we generated also showed reduced replication kinetics which were not 
as large (1-2 log reduction at 24 hpi and identical titers at 48 hpi, Fig 7B) as that reported 
by Rossman et al, (~3 logs at 24hpi and ~5 logs at 48hpi) when compared to wildtype 
rUd (30). Although both growth curves were performed at the same 0.001 MOI, the 
amount of infectious virus was measured differently, plaque assay versus TCID50 assay. 
However, titration of stocks of rUd M2AlaHelix by the two assays showed comparable 
titers (data not shown) indicating the method of detecting infectious virus was not 
responsible for the discrepancy in attenuation.  
 This study sought to investigate whether the membrane proximal residues 46-69 
of the M2 protein cytoplasmic tail were required for the function of M2 during virus 
replication. Given the fact that numerous mutations were made in this region of the M2 
protein and in both complementation assays and recombinant viruses these mutations 
caused little, if any, attenuation in virus replication, we conclude that the region is 
tolerable of numerous amino acid substitutions before protein function is compromised. 
Protein structure, rather than individual amino acid identity, may be critical for the 
function of this region of the M2 protein. It will be important to utilize a structural 
biology approach in order to gain further knowledge about the role of this region on M2 
function.  
 
Acknowledgements 
We would like to thank the members of the Pekosz laboratory for helpful comments and 
discussions. This study was supported by the Eliasberg and Marjorie Gilbert Foundations, 
and NIH R01 AI 053629. 
113 
 
Figure Legends 
 
Figure 1. Sequence and structural location of M2 cytoplasmic tail amino acids. A) 
Conservation of residues 46-69 of the M2 protein among H1N1 (virus sequences prior to 
2009) and H3N2 influenza A virus strains. B) Sequence of residues 46-69 of wildtype 
M2 protein and alanine substitutions. The amphipathic helix is highlighted in yellow (34). 
C-E) Structures of M2 proteins (residues 22-62) with mutated amino acids in green. 
Residue 22 appears at the top of the structures on the left. The structures on the right are 
rotated 90⁰ as indicated in order to view the cytosolic face of the M2 tetramer. C) 
M2UdCYTO - Y52, R53, E56, H57, and K60; D) M2UdPORE - I51, F54, and F55; E) 
M2UdHelix - F47, F48, I51, Y52, and F55. Structures were generated using PyMol from 
PDB code 2LOJ. 
 
Figure 2. Expression and oligomerization of mutant M2 proteins. A) MDCK cells 
stably expressing the indicated M2 proteins were analyzed by Western blotting in order 
to determine (A) the overall expression under reducing conditions and (B) the presence of 
disulfide linked oligomers under non-reducing conditions. Monomeric M2 and the cell 
protein loading control, β-actin, are indicated in (A) and monomers, dimers, and 
tetramers of M2 are indicated in (B). 
 
Figure 3. Complementation of M2-deficient viruses by expression of mutant M2 
proteins. MDCK cells stably expressing the indicated M2 protein were infected at an 
MOI of 0.001 with a recombinant influenza A virus that does not encode the full-length 
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M2 protein. The amount of infectious virus at each time point was determined by TCID50 
assay on cells expressing wildtype M2. Complementation of rUd M2Stop virus (A and B) 
or rWSN M2Stop virus (C and D) infectivity on cells expressing the indicated M2 
protein. The mean and standard error of the mean of triplicate samples are graphed from a 
representative experiment. The limit of detection is marked by a horizontal dotted line.  
 
Figure 4. Plaque size and replication kinetics of recombinant viruses expressing 
mutated M2 proteins. (A and C) Plaque diameter of MDCK cells infected with the 
indicated recombinant viruses at 3 days post infection (dpi). The cells were fixed and 
stained with a Naphthol Blue Black solution and individual plaque diameters were 
measured from scanned images using ImageJ. A representative example is shown from 
triplicate experiments. Student t-tests were performed to determine significant differences 
as compared to wild type virus. (B and C) MDCK cells were infected at an MOI of 0.001 
with the indicated recombinant virus. At the indicated hours post infection (hpi), cell 
supernatants were collected and the numbers of infectious virus particles were 
determined by TCID50 assay on M2-expressing cells. The mean and standard error of the 
mean of triplicate samples are graphed from a representative experiment. The limit of 
detection is marked by a horizontal dotted line. 
 
Figure 5. Complementation of a recombinant virus expressing M2Ala67-79. (A-C) 
MDCK (A), M2Ud-expressing (B), and M2UdAla67-69-expressing cells (C) were 
infected at an MOI of 0.001 with the indicated recombinant virus. At the indicated hpi, 
cell supernatants were collected and the numbers of infectious virus particles were 
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determined by TCID50 assay on cells expressing wildtype M2. The mean and the standard 
error of the mean of triplicate samples are graphed from a representative experiment. The 
limit of detection is marked by a horizontal dotted line. (D) MDCK cells were infected at 
an MOI of 0.5 with the indicated recombinant virus. At 16hpi, expression of M2 and the 
cell protein loading control, β-actin, were compared in cell lysates by Western blot. 
 
Figure 6. Expression and function of M2UdAlaHelix protein. Western blot analysis of 
MDCK cells stably expressing either wildtype M2Ud or M2UdAlaHelix. (A) The total 
expression of M2 protein under reducing conditions and (B) the presence of disulfide 
linked oligomers under non-reducing conditions. Monomeric M2 and the cell protein 
loading control, β-actin, are indicated in (A) and monomers, dimers, and tetramers of M2 
are indicated in (B). (C and D) MDCK cells stably expressing the indicated M2 protein 
were infected with the indicated recombinant virus that does not encode the full-length 
M2 protein at an MOI of 0.001. The amount of infectious virus at each time point was 
determined by TCID50 assay on cells expressing wildtype M2. The mean and standard 
error of the mean of triplicate samples are graphed from a representative experiment. The 
limit of detection is marked by a horizontal dotted line. 
 
Figure 7. Characterization of a recombinant virus expressing M2AlaHelix. (A) 
Plaque diameter of MDCK cells infected with recombinant viruses expressing either 
wildtype M2 or M2AlaHelix at 3dpi. The individual and average diameters of plaques 
were determined. A representative example is shown from triplicate experiments. (B) 
MDCK cells were infected at an MOI of 0.001 with the indicated viruses. At the 
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indicated hpi, cell supernatants were collected and the numbers of infectious virus 
particles were determined by TCID50 assay on M2-expressing cells. The mean and 
standard error of the mean of triplicate samples are graphed from a representative 
experiment. The limit of detection is marked by a horizontal dotted line. (C) MDCK 
cells, infected with 500,000 TCID50 of indicated virus, were stained for 
immunofluorescence at 15hpi and visualized by microscopy. The percent and average 
percent of infected cells showing filaments were determined from 20 non-overlapping 
images taken with an epifluorescence microscope. One representative experiment is 
shown.  (D) MDCK cells were infected at an MOI of 5 with the indicated viruses. At 
12hpi, supernatants were collected and virus particles were concentrated by 
ultracentrifugation through 35% sucrose in PBS, resuspended in PBS, and equal volumes 
were analyzed along with the cell lysates by Western blotting under reducing conditions. 
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Figure 1. Sequence and structural location of M2 cytoplasmic tail amino acids.   
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Figure 2. Expression and oligomerization of mutant M2 proteins.   
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Figure 3. Complementation of M2-deficient viruses by expression of mutant M2 
proteins.   
A B
C D
rUd M2Stop
24 48 721
0
1
2
3
4
5
6
7
8
9
MDCK
M2Ud
M2UdAla46-48
M2UdAla49-51
M2UdAla52-54
M2UdAla55-57
M2UdAla58-60
Inp
ut
hpi
Lo
g
TC
ID
50
/m
L
rUd M2Stop
24 48 721
0
1
2
3
4
5
6
7
8
9
MDCK
M2Ud
M2UdAla61-63
M2UdAla64-66
M2UdAla67-69
M2UdAlaCYTO
M2UdAlaPORE
Inp
ut
hpi
Lo
g
TC
ID
50
/m
L
rWSN M2Stop
24 48 721
0
1
2
3
4
5
6
7
8
9
MDCK
M2Ud
M2UdAla46-48
M2UdAla49-51
M2UdAla52-54
M2UdAla55-57
M2UdAla58-60
Inp
ut
** * **
hpi
Lo
g
TC
ID
50
/m
L
rWSN M2Stop
24 48 721
0
1
2
3
4
5
6
7
8
9
MDCK
M2Ud
M2UdAla61-63
M2UdAla64-66
M2UdAla67-69
M2UdAlaCYTO
M2UdAlaPORE
Inp
ut
hpi
Lo
g
TC
ID
50
/m
L
* ***
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Plaque size and replication kinetics of recombinant viruses expressing 
mutated M2 proteins.   
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Figure 5. Complementation of a recombinant virus expressing M2Ala67-79.   
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Figure 6. Expression and function of M2UdAlaHelix protein.   
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Figure 7. Characterization of a recombinant virus expressing M2AlaHelix. 
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CHAPTER 4 
 
The influenza C virus CM2 protein can alter intracellular pH and its 
transmembrane domain can substitute for that of the influenza A virus M2 protein 
and support infectious virus production 
 
 
This chapter is reprinted here essentially as published. 
 
Shaun M. Stewart and Andrew Pekosz. 
J Virol doi:10.1128/JVI.05681-11 (2011).  
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Abstract 
 The influenza C virus CM2 protein and a chimeric influenza A virus M2 protein 
(MCM) containing the CM2 transmembrane domain were assessed for their ability to 
functionally replace the M2 protein. While all three proteins could alter cytosolic pH to 
varying degrees when expressed from cDNA, only M2 and MCM could at least partially 
restore infectious virus production to M2-deficient influenza A viruses. The data suggest 
that while the CM2 ion channel activity is similar to that of M2, sequences in the 
extracellular and/or cytoplasmic domains play important roles in infectious virus 
production.  
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 The influenza A virus M2 protein is a homotetrameric, type III integral membrane 
protein that functions at several stages of the viral life cycle (24). The proton-selective 
ion channel activity of M2 (4, 18) mediates the release of viral ribonucleoprotein 
complexes (vRNPs) from matrix (M1) and viral membranes, allowing migration of 
vRNPs to the nucleus (9, 15, 23) and also raises the pH of the exocytic pathway, thereby 
preventing premature low pH-induced conformational changes in hemagglutinin (HA) (5, 
26). The cytoplasmic tail of M2 is also required for efficient genome packaging into 
budding virus particles (8, 16, 17). M2 has also been proposed to be mediate membrane 
scission, however, in the absence of M2, infected and transfected cells release virus 
particles and virus like particles, respectively (2, 3, 8, 14, 25). 
 The influenza C virus CM2 protein is an integral membrane protein generated 
after proteolytic cleavage of an internal signal peptide of the p42 protein (10, 13, 22). 
CM2 forms disulfide-linked homotetramers (12, 21) and has been shown to conduct Cl- 
ions (11) or perhaps protons (19). CM2 has been shown to be involved in the release of 
vRNPs during virus uncoating and in packaging of vRNPs during virus assembly (7). 
CM2 is also able to raise the pH of the exocytic pathway; however, the role of this 
activity during influenza C virus replication is currently unclear (1). This study sought to 
investigate whether full length CM2 or a chimeric M2 protein containing the CM2 
transmembrane domain could functionally substitute for the influenza A virus M2 
protein.  
CM2, normally generated from proteolytic cleavage from p42, can be expressed 
efficiently from cDNA using the vaccinia virus-bacteriophage T7 polymerase expression 
system (21) but expression levels are low from plasmids that rely on host cell 
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transcription machinery. Efficient plasmid-based expression of CM2 was achieved by 
deleting the p42 internal signal peptide from the expression plasmid (20), most likely 
because of the elimination of a mRNA splice donor site present in the RNA 
corresponding to the signal peptide. The glycosylation site was eliminated by mutating 
Thr at residue 37 to Ala and epitope tags for the antibodies 3F10 (anti-hemagglutinin 
epitope) and 14C2 (anti-M2 epitope) were added at the carboxy-terminus in order to 
facilitate detection of the protein (Fig 1A). In order to determine if the ion channel 
activity of CM2 can substitute for that of M2, a construct was generated with the 
extracellular and cytplasmic tail of M2 and the TM of CM2 (MCM), Fig 1A. 
 Because some reports show that M2 and CM2 have differential ion channel 
activity yet both are able to raise the pH of the secretory pathway (1, 5, 6, 11, 19), the ion 
channel activity of the two proteins was compared in an assay that measures pH-
dependent changes in eYFP fluorescence (8). Whereas low-pH treatment of 293T cells 
co-transfected with eYFP and an empty vector yielded no change in mean fluorescence 
intensity (MFI) over time, low-pH treatment of cells co-transfected with eYFP and M2 
from A/Udorn/72 (M2Ud) resulted in ~40% decrease in MFI (Fig 1B-C). Low-pH 
treatment of cells co-transfected with eYFP and CM2 only resulted in ~25% decrease in 
MFI (Fig 1D), indicating the CM2 protein was able to modulate the cytoplasmic pH of 
transfected cells but not to the same extent as the M2 protein. The MCM protein induced 
a reduction in eYFP fluorescence which resembled that of CM2 (Fig 1E), suggesting that 
substitution of the CM2 TM for that of M2 conferred ion channel activity that resembled 
that of CM2. The level of expression of M2, CM2 and MCM in transfected 293T cells 
was comparable (Fig 1C- E), indicating that the decreased pH changes induced by CM2 
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and MCM compared to M2 were not attributable to differential protein levels but most 
likely reflected altered ion channel activity.  
 In order to determine if CM2 and MCM were able to complement a M2-null 
influenza A virus, clonal MDCK cell lines stably-expressing the proteins were generated. 
Total expression of CM2 and MCM are shown relative to cell lines expressing M2Ud or 
M2 from A/WSN/33 with a mutation conveying amantadine resistance (M2WSN N31S) 
(Fig 2A) (27, 28). The expression level of MCM was similar to that of M2, while the 
CM2 protein expression level was only 2% of the levels of M2. However, even trace 
amounts of M2 protein can functionally complement an M2-null influenza A virus (17) 
so the levels of CM2 expression are expected to be sufficient for the complementation 
assay. MCM was able to form disulfide-linked oligomers, similar to the M2 and CM2 
proteins (Fig 2B). In order to determine if constitutive expression of CM2 or MCM 
prevented replication of influenza A virus, recombinant A/Udorn/72 (H3N2, rUd) and 
recombinant A/WSN/33 (H1N1, rWSN) were titered on the cell lines (Fig 2C). Both rUd 
and rWSN had similar titers on all cell lines tested, suggesting that expression of CM2 or 
MCM does not inhibit influenza A virus infection. To assess the ability of CM2 and 
MCM to substitute for M2, the recombinant M2-null viruses rUd M2Stop & rWSN 
M2Stop (8, 27) were titered on the cell lines (Fig 2C). Both rUd M2Stop and rWSN 
M2Stop showed decreased titers on CM2-expressing cells compared to M2-expressing 
cells, indicating CM2 cannot functionally replace M2. When comparing MCM to M2-
expressing cells, rUd M2Stop had similar titers while rWSN M2Stop showed a decrease 
in titer, demonstrating that the MCM protein can complement rUd M2Stop but not rWSN 
M2Stop, which suggests that the CM2 ion channel activity can functionally substitute for 
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that of M2 in some influenza A virus strains. However, given the low level of CM2 
expression, it remains to be determined if overexpression of the CM2 protein to levels 
much higher than those needed for M2 complementation, can partially complement an 
M2-null influenza virus. 
 The ability of MCM to substitute for M2 was also tested in multi-step growth 
curves (Fig 2D-E). Neither rUd M2Stop nor rWSN M2Stop were able to grow in CM2-
expressing cells despite the fact that the level of CM2 expression was higher than that 
needed to complement these viruses with M2 protein (8, 16, 17). MCM-expressing cells 
did support growth of both viruses, but the growth of rWSN M2Stop was more attenuated 
than rUd M2Stop. Since CM2 expression could not complement while MCM expression 
could partially complement two different M2-null viruses, we conclude that that the ion 
channel activity of CM2 can replace that of M2; however, the ectodomain and/or the 
cytoplasmic tail of M2 are required during influenza A virus replication. 
 M2 mutations that cause strain specific defects in growth of either rUd or rWSN 
have previously mapped to the M1 protein (2, 8, 16). The ability of MCM expression to 
complement rUd M-WSN M2Stop (expressing 7 segments from Ud, M1 from WSN, and 
no M2) growth was comparable to its ability to complement rUd M2Stop (Fig 2D&F). 
Likewise, the ability of MCM expression to complement rWSN M-Ud M2Stop 
(expressing 7 segments from WSN, M1 from Ud, and no M2) growth was comparable to 
its ability to complement rWSN M2Stop (Fig 2E&G). Together, these data indicate that 
the decreased ability of MCM to complement rWSN M2Stop maps to viral sequences 
outside of the M1 protein. 
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 The inability of CM2 to complement M2-null viruses could be  due to a defect in 
particle budding. Virus particles from high MOI infections were concentrated by 
ultracentrifugation through 35% sucrose and analyzed by Western blot and TCID50 assay 
(Fig 3). As previously published, rUd M2Stop virus particles from MDCK cells are 
released but are defective in the incorporation of full length NP (NPa) and have lower 
infectious virus titers relative to total HA  (Fig 3A-C) (8). rWSN M2Stop virus particles 
grown on MDCK cells also have decreased titer relative to total HA but increased release 
and cleavage of HA  (Fig 3D-E). Both M2-null viruses grown on CM2-expressing cells 
showed similar phenotypes compared to those grown on MDCK cells (Fig 3). However, 
rUd M2Stop virus particles grown on MCM-expressing cells incorporated MCM and did 
not show the decreased incorporation of NPa observed in virus particles isolated from 
MDCK and CM2-expressing cells (Fig 3A-C). rWSN M2Stop virus particles grown on 
MCM-expressing cells also had similar structural protein incorporation compared to 
particles from M2-expressing cells. The ratio of titer to HA (a measure of the infectivity 
of the particles) of viruses grown on MCM-expressing cells was intermediate of that from 
those grown on MDCK or CM2-expressing cells versus M2-expressing cells (Fig 3C&E). 
Taken together this data demonstrates that expression of MCM, but not CM2, is able to 
complement the defect of NPa incorporation present in viruses grown on MDCK cells but 
that the particles from MCM-expressing cells still have a defect in infectivity which is 
more apparent in rWSN M2Stop versus rUd M2Stop.  
 Negative stain electron microscopy was performed on the purified rUd M2Stop 
virus particles in order to assess any morphological differences in virus particles grown 
on the various cell lines. rUd M2Stop particles grown on MDCK or CM2-expressing 
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cells had a smaller average diameter and higher particle/TCID50 ratios than those grown 
on M2-expressing cells (Fig 4). Virus particles isolated from MCM-expressing cells were 
of similar size to those grown on M2-expressing cells, but had slightly higher 
particle/TCID50 ratios (Fig 4F). All cell lines produced comparable numbers of particles 
(Fig. 4F). These data indicate that the infectivity of the virus particles correlated with the 
size of the particles, and that MCM, but not CM2, could partially complement the rUd 
M2stop virus.  
These studies suggest that influenza A virus produced in the absence of M2 or in 
the presence of CM2 has a defect in the incorporation of NPa (and most likely, vRNA), 
smaller particles, an increased ratio of total to infectious particles, and absence of growth 
in multi-step growth curves. The level of CM2 expression was higher than the level of 
M2 expression needed for complementation, however we cannot rule out the fact that 
higher levels of CM2 expression might lead to some degree of complementation or that 
the addition of C-terminal epitope tags may be interfering with CM2 protein function. 
Virus particles produced in the presence of MCM incorporate a normal level of NPa and 
are of normal size but have a slightly reduced infectivity. We hypothesize that the defect 
in infectivity of virus particles grown on MCM-expressing cells is due to the differential 
ion channel activity of the MCM protein versus the M2 protein. The ion channel activity 
(Fig 1) shows that MCM does not lower the pH of the cytoplasm as efficiently as M2, 
most likely leading to a decreased ability to release vRNPs during virus entry. 
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Figure Legends 
 
Figure 1. Schematic and ion channel activity of M2, CM2, and MCM. A) Schematic 
of the ectodomain (Ecto), transmembrane domain (TM), and cytoplasmic tail (Cyto) of 
wildtype M2, CM2, and MCM. Amino acid numbers are indicated. Sequences recognized 
by the HA (black box) and M2 (hatched box) antibodies are also shown. B-E) The ability 
of M2, CM2, and MCM to conduct ions was indirectly measured using the pH-sensitive 
fluorescent protein eYFP. 293T cells were transiently transfected with plasmids encoding 
eYFP and either an empty pCAGGS expression plasmid or a pCAGGS plasmid 
expressing the indicated protein. The next day, cells were detached and resuspended in 
media at either pH 7.4 or pH 5.8 and analyzed by flow cytometry. The mean fluorescence 
intensity (MFI) of 10,000 cells was determined every 15 sec. The change in MFI versus 
time is plotted from a representative experiment performed at least twice. Solid lines 
represent curve fits to one phase exponential decay models and dotted lines represent no 
change in MFI. The expression levels of M2, CM2, and MCM in eYFP positive cells was 
determined by flow cytometry using the 14C2 antibody and a goat anti-mouse antibody 
conjugated to AlexaFluor 647. The MFI and standard deviation are presented in each 
panel.  
 
Figure 2. Expression, oligomerization, and complementation ability of M2, CM2, 
and MCM. A and B) MDCK cells or MDCK cells stably expressing the indicated 
proteins were analyzed by Western blotting in order to determine (A) the total expression 
under reducing conditions and (B) the presence of disulfide linked oligomers under non-
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reducing conditions. Antibodies were α-M2 MAb 14C2 (1:500), α-β-actin MAb 
(1:10,000, Abcam AC-15), and goat α-mouse IgG conjugated to AlexaFluor 647 (1:500, 
Invitrogen). Monomeric proteins and the cell protein loading control, β-actin, are 
indicated in (A) and monomers, dimers, and tetramers are indicated in (B). Relative 
expression levels of M2, CM2, and MCM, normalized to M2WSN N31S, are listed 
below the corresponding lane. C) Titers of the indicated recombinant virus were 
determined by TCID50 assay on MDCK cells or MDCK cells stably expressing the 
indicated protein. The mean and the standard error of the mean are graphed from two 
independent experiments. D-G) MDCK cells or MDCK cells stably expressing the 
indicated protein were infected at an MOI of 0.001 with the indicated recombinant 
influenza A viruses. The amount of infectious virus at each time point was determined by 
TCID50 assay on cells expressing wildtype M2. The mean and the standard error of the 
mean are graphed. The limit of detection is marked by a horizontal dotted line. Infectious 
virus production from 24-72 hr was analyzed using mixed ANOVAs with time and virus 
as independent variables using Prism 4.0. Statistical differences between viruses grown 
on M2-expressing cells and MCM-expressing cells are indicated, ***p<0.001. 
 
Figure 3. Analysis of structural proteins incorporated into M2-null viruses. rUd 
M2Stop (A-C) or rWSN M2Stop (D-E) virus particles grown on the indicated cell lines 
were concentrated by ultracentrifugation through 35% sucrose in PBS, resuspended in 
PBS, and analyzed by Western blotting under reducing conditions and by TCID50 assay 
on wildtype M2-expressing cells expressing. A and D) Incorporation of various structural 
proteins into M2-null viruses are indicated from images scanned using an FLA-5000. B) 
141 
 
The relative amount of NPa incorporated into rUd M2Stop virus particles was quantified 
from Western blots and is indicated as a ratio to total HA0. C and E) The relative titer of 
each sample is indicated as a ratio of the titer versus total HA0, as determined by Western 
blot analysis. The mean and the standard error of the mean are graphed from at least two 
independent experiments and the Western blots represent one of the quantified replicates. 
 
Figure 4. Morphology of M2-null virus grown on cell lines expressing M2, CM2, or 
MCM. rUd M2Stop virus particles grown on MDCK cells or MDCK cells stably 
expressing the indicated protein were concentrated through PBS containing 35% sucrose 
as in Fig 3. Samples were mixed 1:1 with a 1:500 dilution of 100nm Nanosphere beads 
(Thermo Scientific). 2uL was allowed to dry onto a 400 mesh carbon and parlodion 
coated copper grid, negatively stained with filtered 1% aqueous phosphotungstic acid pH 
7.0, and blot dried with filter paper. Samples were viewed on a Hitachi H-7600 TEM 
operating at 80 kV and digitally captured with an AMT CCD at 1k x 1k resolution. A-E) 
Representative electron micrographs of virus particles grown on various cell lines, 
including the average and standard deviation of the particle diameter as measured on the 
longest axis (n≥17). Scale bar represents 100nm. F) The total particles (determined from 
the known concentration of Nanosphere beads (29)) and the ratio of total particles to 
TCID50 titer are graphed from three separate experiments. 
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Figure 1. Schematic and ion channel activity of M2, CM2, and MCM.   
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Figure 2. Expression, oligomerization, and complementation ability of M2, CM2, 
and MCM.   
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Figure 3. Analysis of structural proteins incorporated into M2-null viruses.   
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Figure 4. Morphology of M2-null virus grown on cell lines expressing M2, CM2, or 
MCM. 
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Conclusions 
 The highly conserved type III integral membrane protein M2 consists of 97 amino 
acids and forms disulfide-linked tetramers which have a pH-gated, proton-selective ion 
channel activity (10, 32, 35). M2 is required during virus entry, where it translocates 
protons into the virion interior which allows for the dissociation of viral 
ribonucleoprotein complexes (vRNPs) from the site of virus-cell membrane fusion, 
thereby allowing nuclear transport of the vRNPs (18, 28, 34). M2 is also required during 
virus assembly where it is important for proper incorporation of vRNPs into budding 
virus particles (7, 16, 21, 29, 30). 
M2 contains several domains, an N-terminal ectodomain, a transmembrane 
domain, and a C-terminal cytoplasmic tail. The cytoplasmic tail can be divided into two 
regions based upon deletion mutants and function mapping, the membrane proximal 
region, residues 46-69, and the membrane distal region, residues 70-97 (Fig 1). The 
membrane distal region has been studied extensively and is required for proper budding 
and vRNP incorporation (7, 16, 21, 29, 30). However, much less is known about the role 
of the membrane proximal region in virus replication. The NMR structure of the 
transmembrane domain and most of membrane proximal region (residues 22-62) was 
recently determined by two groups (38, 40). These structures confirm that residues 48-58 
form an amphipathic helix. This amphipathic helix also seems to stabilize the tetrameric 
structure of M2, particularly at low pH when the ion channel is open. 
The primary aim of this thesis was to determine the role of the membrane 
proximal region of the M2 cytoplasmic tail in M2 incorporation and virus replication. 
Several potential methods of M2 incorporation were previously suggested that 
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encompassed the membrane proximal region including cholesterol binding (39) and 
interactions with M1 (7, 29). I attempted unsuccessfully to co-immunoprecipate 
cholesterol and full length M2 transiently expressed from cDNA. Later, others showed 
that cholesterol could only be pulled down by anti-M2 immunoprecipitations from 
cellular extracts in context of virus infection, ie the co-expression of other viral proteins 
(36). Since this cholesterol co-immunoprecipitation requires other viral proteins, some of 
which, HA and NA, are located at sites enriched in cholesterol, and M2, NA, and HA all 
get incorporated into virus particles, it is probable that this cholesterol co-
immunoprecipitation may be mediated by indirect interactions with other viral proteins. 
Indeed, I found that the cholesterol binding motif in M2 is not required for M2 
incorporation or virus replication in tissue culture in either a trans-complementation 
system or in recombinant viruses expressing mutant M2 proteins (43). Alteration of the 
cholesterol binding motif did modestly attenuated the morbidity and mortality induced by 
recombinant virus in mice, suggesting that this region may be a virulence factor (43). 
I also studied the other hypothesis, that interactions between M1 and M2 drive the 
incorporation of M2. Two M1 binding sites within the M2 cytoplasmic tail have been 
previously mapped, one in the membrane proximal region and another in the membrane 
distal region (29, 30). Deletion or mutation of amino acids in the membrane distal region 
lead to decreased vRNA incorporation but do not affect M1 or M2 incorporation (7, 16, 
29, 30). I used scanning and directed alanine mutagenesis in trans-complementation 
assays and recombinant viruses to determine if the membrane proximal region of M2 was 
important for M2 incorporation and virus replication. I determined that this region can 
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sustain numerous linear and structure based mutations with little, if any, effect on virus 
replication and M2 incorporation (42).  
 My last aim started as an attempt to use chimeric proteins between influenza A 
virus M2 and an M2 homolog in influenza C virus, CM2, to determine which regions of 
M2 were most important for M2 function, incorporation, and virus replication. 
Unfortunately, several of the chimeric constructs were not expressed at the cell surface 
correctly, possibly due to differences in the normal way in which M2 and CM2 undergo 
membrane insertion during translation. This issue prevented a complete analysis of which 
domains of M2 were necessary and sufficient for M2 incorporation and virus replication. 
However, one construct, an M2 chimera expressing the CM2 transmembrane domain 
(MCM), was expressed properly and utilized, along with M2 and CM2, in order to 
compare the ion channel function and the ability of the transmembrane of CM2 to replace 
that of M2 during virus infection. I determined that CM2 and MCM both had similar 
abilities to alter the cytosolic pH when expressed at the cell surface, but that only MCM 
was able to rescue the infectivity of an M2-null virus (41). This further confirmed that 
residues in the ectodomain and cytoplasmic tail of M2 are important in the assembly of 
infectious influenza A virus. This also demonstrated for the first time that the ion channel 
activity of CM2, although different from M2, is sufficient to induce the release of 
influenza A vRNPs during virus entry. 
 
Current Budding Model 
 Combining the data presented in this thesis along with other recently published 
data, I propose the following model for virus budding (Fig 2). After viral transcription 
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and translation, the major structural proteins and vRNPs traffic to the plasma membrane. 
The glycoproteins HA and NA traffic with detergent-resistant membrane microdomains 
to the cell surface (11, 26, 47). At early times after infection, M2 has a more random 
distribution across the cell surface than HA and NA, does not co-localize in one 
dimension with HA in immunogold labeled thin-section electron micrographs (TEM), 
and is susceptible to cold detergent extraction  (26, 39, 47). However, at later times after 
infection, M2 is seen to co-localize two-dimensionally with HA in immunogold labeled 
electron micrographs of planar sheets of plasma membrane (7). This suggests that as viral 
proteins begin to accumulate at the cell surface late during infection, M2 and HA begin to 
localize to similar regions despite remaining in unique microdomains of the plasma 
membrane (Fig 2A). 
Some evidence suggests that Rab11, a small GTP-binding protein involved in 
trafficking of non-raft proteins to the apical recycling endosome (ARE) en route to the 
plasma membrane, is required for M2 but not HA trafficking to the plasma membrane 
(11, 37). M2 has been shown previously to be important for vRNP incorporation (7, 16, 
29, 30) and my studies show that in the absence of M2, budded virus particles are indeed 
smaller, probably reflecting a defect in vRNP incorporation (41). I propose that M2 and 
vRNPs directly interact while in transport to or after M2 arrives at the plasma membrane. 
Like M2 trafficking, correct trafficking of vRNPs also require Rab11 (2, 12, 31). This 
suggests, but does not definitely prove, that M2 and vRNPs interact at the ARE during 
transport and arrive at the plasma membrane together. Either way, interaction and 
localization together at the plasma membrane (Fig 2B) may occur before, after, or at the 
same time as M1 begins to bind to the membrane (Fig 2C) and oligomerize (Fig 2D). 
155 
 
 M1 has the inherent ability to bind membranes, oligomerize, and induce particle 
formation in the absence of the other viral proteins (15, 17, 22, 46). However, studies also 
show that M1 interacts with the HA and NA cytoplasmic tails and that this interaction 
directs M1 to detergent-resistant membrane microdomains, where HA and NA are 
enriched (1). Therefore, this proposed budding model emphasizes that these interactions 
between M1 and the glycoproteins may assist M1 oligomerization and increase viral 
budding (Fig 2D). 
 TEM and cryo-electron microscopy (cryo-EM) reveal that in filamentous 
influenza virus particles, the vRNPs are located at the distal end of the budding particles 
(6, 33). Given that M2 is important in vRNP incorporation and that vRNPs, when 
incorporated, are located at the distal end of particles, I propose that M2 interacting with 
vRNPs at the plasma membrane becomes the seed with which M1 interacts to drive 
budding (Fig 2E-F). However, in the absence of M2, virus particles are still produced 
demonstrating M2 is not required for budding (9, 16, 20, 41), and in the presence of M2, 
empty particles are formed in addition to infectious particles (33). Together these data 
suggest that either some particles are seeded by M2 which do not have bound vRNPs or, 
even when M2 is present, M1 induces some particles to form without the M2/vRNP seed. 
These particles, without vRNPs would be non-infectious and be in agreement with why 
few particles are detected that do not contain a partial complement of eight vRNPs (33). 
M1 forms a helical lattice around the vRNPs just inside the viral membrane and the 
cytoplasmic tails of HA, NA, and M2 protrude through holes in this lattice given the 
glycoproteins regular order on the surface of the virus (6). 
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 This model does not address how particles undergo membrane scission and are 
released. There is little data on cellular factors that might be involved in this step. M2 and 
a peptide corresponding to the M2 amphipathic helix, have been shown to induce 
membrane curvature and scission in unilamellar vesicles and were suggested to mediate 
membrane scission and virion release (37). However, virus-like particles (VLPs) (7, 8, 
15, 24, 25, 44) and virions (9, 16, 20) can be released in the absence of M2. Perhaps, like 
respiratory syncytial virus (RSV), influenza membrane scission is mediated by cellular 
factors which bind Rab11 (5, 45). 
 
Future Directions 
 These studies provide evidence that the cholesterol binding motif is not important 
during replication in tissue culture but partially modulates pathogenesis in mice. 
Determining why viruses with an alteration of this motif are attenuated in mice will be 
important. Perhaps cholesterol binding by M2 can act to sequester cholesterol thereby 
modulating normal cellular functions. However, the fact that the type of cholesterol 
binding motif found in M2 is generally not one identified as cholesterol sequestering 
argues against this hypothesis. Nonetheless, it should be evaluated by comparing the 
effect of cholesterol metabolism in cells expressing either wildtype M2 or the cholesterol 
binding motif mutant. It would also be interesting to study the effect of cholesterol levels 
on virus replication; however, cholesterol depletion has been shown to have multiple 
non-M2 associated affects on influenza virus replication including disruption of HA and 
NA containing membrane microdomains, increased particle budding, and decreased 
particle stability (3). 
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Given that cholesterol can only be immunoprecipitated in the presence of the 
expression of the other viral proteins (36), it is also possible that the role of this region as 
a virulence factor is not related to cholesterol binding. Indeed the first 60 amino acids of 
M2, which include the cholesterol binding motif, are able to bind Beclin-1 and inhibit the 
maturation of autophagosomes (14). Inhibition of this pathway by HIV blocks autophagy 
mediated virion degradation and could also do so for influenza A virus (23). As such, it 
should be determined if mutation of the residues in the cholesterol binding motif prevents 
the inhibition of autophagosome maturation. 
Although the alanine mutagenesis of the membrane proximal region showed, little 
or no effect on replication of virus, it will be interesting to see if these mutants, like the 
virus expressing the cholesterol binding mutant, are attenuated in mice. If some are 
attenuated and others are not, it would serve to further define the region of M2 that may 
be a virulence factor in mice. Along with morbidity and mortality, the levels of viral 
replication and virus-induced cytokine production should be determined since both are 
associated with severe influenza pathogenesis. 
 Experiments also showed that a recombinant rUd (H3N2) influenza virus (rUd 
M2AlaHelix) expressing five alanine substitutions in the membrane proximal region of 
M2, at residues F47, F48, I51, Y52, and F55, grew to lower infectious titers at 24hpi but 
produced similar levels of infectious virus at 48hpi compared to wildtype (42). 
Furthermore, there was no apparent defect in incorporation of HA, M1, or NP in this 
virus. These findings differed from a similar recombinant virus previously published that 
produced 4-5 logs less infectious virus at all times hpi tested and had decreased 
incorporation of NP (36). In order to confirm the results of the recombinant virus, I also 
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used a trans-complementation system to test the requirement of these five amino acids on 
virus replication. Although complementation of M2-null viruses with the expression of 
this mutant did decrease production of infectious virus at all times hpi, it was only 
decreased by ~1-2 logs (42). These findings together contradict the suggestion that these 
five amino acids are required in tissue culture as reported (36). It will be important to test, 
side-by-side, the rUd M2AlaHelix generated previously with the one described here in 
order to reconcile their phenotypic differences. 
 All mutations to date in the M2 amphipathic helix have focused on maintaining 
the structure of the helix while altering the identities of individual amino acids or altering 
charge faces. It would be beneficial in future studies to either make mutations that are 
predicted to interrupt the helical structure, perhaps by inserting prolines and/or glycines, 
or to insert a sequence between the transmembrane and amphipathic helix that is unable 
to form a helix. 
 Another finding in this dissertation that should be followed up relates to the ion 
channel activity of CM2. It has previously been suggested that CM2 is not required to 
pump ions inside the uncoating virion in influenza C virus, like it is in influenza A virus, 
because low pH did not separate M1 from vRNPs (48). However, two lines of evidence 
suggest that a low pH burst may in fact also be required for influenza C virus. First, CM2 
has ion channel activity and can result in lowered pH (4, 19, 41). Second, similar to M2, 
CM2 is required for nuclear migration of vRNPs during virus uncoating (13). In light of 
the data presented in this thesis, I hypothesize that for influenza C virus low pH is 
required to separate M1/vRNPs from membranes but not each other. Alternatively, since 
CM2 may be able pump chloride ions (19), the separation of M1/vRNPs might occur at 
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different relative salt concentrations compared to influenza A virus M1/vRNPs. Future 
work should reevaluate the ability of low pH to separate influenza C virus M1/vRNPs 
from membranes and M1 from vRNPs at various pH levels and salt concentrations. 
Related to the ability of CM2 to lower cytosolic pH, it was interesting that 
expression of MCM but not CM2 was able to complement M2-null viruses in a strain 
specific manner. MCM complemented rUd strains better than rWSN (H1N1) M2-null 
strains and this phenotype did not map to M1 as have so many other strain specific effects 
of M2 have in the past (7, 16, 29). One hypothesis about why MCM is able to 
complement rUd strains better than rWSN strains of influenza is that the M2-mediated 
release of vRNPs during entry requires different pH in the two strains. This is in 
agreement with the findings that M2 incorporation is much lower in wildtype rUd 
compared to rWSN and that MCM has decreased abilities to alter pH compared to M2 
(41). It will be important to test this hypothesis by purifying M1/vRNP complexes from 
either cells or virus particles and determine the pH that is required for separation of M1 
and vRNPs from both strains of viruses, as has been done previously to compare other 
influenza reassortants (27). 
 
Implications 
 The M2 protein is required for virus entry and assembly. First generation 
adamantane pharmaceuticals, amantadine and rimantadine, have been available for a 
number of years and work by blocking the ion channel activity of M2. However, 
resistance to these drugs easily arises and most circulating H3N2 strains are already 
resistant to both drugs. Mutations that convey resistance to adamantanes so readily 
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appear in the population probably due to several reasons. One, M2 is required for virus 
replication. Two, very high levels of drug are required in vitro in order to completely 
block ion channel activity and are potentially not achievable in vivo. Lastly, different 
strains may require more or less M2 ion channel activity for replication. Together this 
suggests that M2 is a great drug target but that better drugs must be discovered. Many 
resources are being invested in optimizing adamantanes, but little to date has provided 
promise. This thesis increases our knowledge of M2 and suggests that new drugs should 
target functions of M2 in the ectodomain and cytoplasmic tails of the protein. 
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Figure Legends 
 
Figure 1. Schematic of functional domains of M2. M2 contains three domains, an N-
terminal ectodomain, a transmembrane domain, and a C-terminal cytoplasmic tail. The 
cytoplasmic tail can be artificially divided into two parts based upon function. The 
membrane distal region includes residues 70-97 and has been shown to be important for 
virus budding and vRNP incorporation. The membrane proximal region also contains 
several important functions and was further studied in this thesis. The schematic shows 
an image of the crystal structure of residues 22-62 (PDB 2LOJ) generated with PyMol 
along with lines representing the ectodomain and remainder of the cytoplasmic tail 
(residues 63-97). Extra is the extracellular space, PM is the plasma membrane, and Cyto 
is the cytosol. 
 
Figure 2. Model of infectious influenza A virus assembly. A) After viral transcription 
and translation, the major structural proteins and viral ribonucleoprotein complexes 
(vRNP) accumulate at the plasma membrane. The glycoproteins HA and NA traffic to 
similar membrane microdomains (purple), which resemble lipid rafts. M2 has a more 
random distribution across the cell surface and does not accumulate in HA and NA-
containing microdomains (grey). B) M2, which is known to interact with vRNPs, may do 
so at this time. C) M1 has the inherent ability to bind the inner leaflet of the plasma 
membrane. D) M1, either already bound to the membrane or from a cytoplasmic pool, 
binds the cytoplasmic tails of HA and NA and undergoes oligomerization. The order of 
B-D may be different or the steps may occur simultaneously. E) M1 interacts with M2 
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and initiates membrane curvature and viral budding around the vRNPs. In the absence of 
M2, M1 still induces budding, but vRNP incorporation is impaired. F) After budding is 
initiated, M2 and the vRNPs are located at the distal end of filamentous particles. M1-M1 
interactions direct the continued growth of virus particles by the aggregation and 
incorporation of HA and NA-containing microdomains. At some point, unknown cellular 
factors are probably recruited to the bud and induce membrane scission, releasing the 
virus particle. M1-M1 structure around the distal vRNPs has been omitted for clarity. 
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